var title_f15_29_15824="Innervation of lower airway";
var content_f15_29_15824=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    The innervation of the lower airways depicted in a highly schematic diagram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 574px; height: 435px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the lower airways, two distinct parasympathetic pathways have been identified: cholinergic and noncholinergic. Cholinergic parasympathetic nerves mediate bronchospasm while noncholinergic parasympathetic nerves mediate bronchodilatation. Reflexes differentially regulate these distinct parasympathetic pathways. This differential regulation may be facilitated by the distinct origin of preganglionic parasympathetic nerves arising from regions of the nucleus ambiguous (nA) or the dorsal motor nucleus of the vagus nerves (dmnX), and perhaps through differential processing of afferent input through the nucleus tractus solitarius (nTS). Sympathetic-adrenergic innervation of airway smooth muscle in humans is sparse or nonexistent. Circulating catecholamines are thus likely to be the primary endogenous ligand for b-adrenoceptors on airway smooth muscle. Vagal afferent nerves regulate autonomic reflexes in the lower airways. Multiple subtypes of afferent nerves innervating the airways and lungs have been identified. These afferent nerves regulate autonomic nerve activity, respiration and defensive reflexes such as cough.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mazzone, SB, Canning, BJ. Central nervous system control of the airways: pharmacological implications. Curr Opin Pharmacol 2002; 2:220. Copyright &copy; 2002 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_29_15824=[""].join("\n");
var outline_f15_29_15824=null;
var title_f15_29_15825="Calculator: Hepatitis discriminant function for corticosteroid therapy in alcoholic hepatitis";
var content_f15_29_15825=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"HepatitisCriteria_form\" name=\"HepatitisCriteria_form\" onkeydown=\"clrResults();\" onkeyup=\"HepatitisCriteria_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Hepatitis discriminant function for corticosteroid therapy in alcoholic hepatitis",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          Index = 4.6 * (ProthrombinTime - ControlProthrombinTime) + Bilirubin",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Prothrombin Time",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Prothrombin_Time_param\" onblur=\"HepatitisCriteria_fx(); minMaxCheck();\" onchange=\"HepatitisCriteria_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Prothrombin_Time_unit\" onchange=\"HepatitisCriteria_fx();\" style=\"width:105px;\">",
"              <option value=\"3600|0|hr\">",
"               hr",
"              </option>",
"              <option value=\"60|0|min\">",
"               min",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|sec\">",
"               sec",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Control Prothrombin Time",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Control_Prothrombin_Time_param\" onblur=\"HepatitisCriteria_fx(); minMaxCheck();\" onchange=\"HepatitisCriteria_fx();\" size=\"6\" type=\"text\" value=\"12\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Control_Prothrombin_Time_unit\" onchange=\"HepatitisCriteria_fx();\" style=\"width:105px;\">",
"              <option value=\"3600|0|hr\">",
"               hr",
"              </option>",
"              <option value=\"60|0|min\">",
"               min",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|sec\">",
"               sec",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Bilirubin",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Bilirubin_param\" onblur=\"HepatitisCriteria_fx(); minMaxCheck();\" onchange=\"HepatitisCriteria_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Bilirubin_unit\" onchange=\"HepatitisCriteria_fx();\" style=\"width:105px;\">",
"              <option value=\"0.0584795321637427|0|mcmol/L_Bili\">",
"               mcmol/L",
"              </option>",
"              <option value=\"1|0|mg%_Bili\">",
"               mg%",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mg/dL_Bili\">",
"               mg/dL",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Result:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Index",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Index_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <div id=\"calc_notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       Patients with a score &gt;=32 may benefit from treatment with corticosteroids.",
"      </li>",
"      <li>",
"       Please see appropriate UpToDate topic reviews for further information.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Ramond MJ, Poynard T, Rueff B, Mathurin P, Theodore C, Chaput JC, Benhamou JP. A randomized trial of prednisolone in patients with severe alcoholic hepatitis.",
"        <i>",
"         N Engl J Med",
"        </i>",
"        . 1992 Feb 20;326(8):507-512.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Scott L. Friedman, MD et. al. editors.",
"        <i>",
"         Current Diagnosis &amp; Treatment in Gastroenterology",
"        </i>",
"        . 2nd Ed. (2003).",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_29_15825=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function HepatitisCriteria_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.HepatitisCriteria_form){",
"",
"",
"doCalc = true;",
"if (Prothrombin_Time_param.value.indexOf(',') >= 0){ Prothrombin_Time_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Prothrombin_Time_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Prothrombin_Time_unit.options[Prothrombin_Time_unit.selectedIndex].value.split('|');",
"Prothrombin_Time = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Control_Prothrombin_Time_param.value.indexOf(',') >= 0){ Control_Prothrombin_Time_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Control_Prothrombin_Time_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Control_Prothrombin_Time_unit.options[Control_Prothrombin_Time_unit.selectedIndex].value.split('|');",
"Control_Prothrombin_Time = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Bilirubin_param.value.indexOf(',') >= 0){ Bilirubin_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Bilirubin_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Bilirubin_unit.options[Bilirubin_unit.selectedIndex].value.split('|');",
"Bilirubin = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = 0;",
"Index =  4.6 * (Prothrombin_Time - Control_Prothrombin_Time) + Bilirubin;",
"",
"if (doCalc) Index_param.value = fixDP(Index, dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.HepatitisCriteria_form){",
"",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.HepatitisCriteria_form){",
"",
"Index_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f15_29_15825=null;
var title_f15_29_15826="Vertebral column";
var content_f15_29_15826=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vertebral column",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 620px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Anatomical Chart Company. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_29_15826=[""].join("\n");
var outline_f15_29_15826=null;
var title_f15_29_15827="Bullous pemphigoid in childhood";
var content_f15_29_15827=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F58359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F58359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bullous pemphigoid in childhood",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple tense bullae, inflammatory plaques, erosions, and crusts on the skin of this child with bullous pemphigoid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_29_15827=[""].join("\n");
var outline_f15_29_15827=null;
var title_f15_29_15828="Ambenonium: Patient drug information";
var content_f15_29_15828=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ambenonium: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/6/21603?source=see_link\">",
"     see \"Ambenonium: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F132750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mytelase&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat myasthenia gravis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701483",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ambenonium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bowel block, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have Parkinson's disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697349",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have trouble passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699028",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10769 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-DD2D800F1C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_29_15828=[""].join("\n");
var outline_f15_29_15828=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132750\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022650\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022649\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022654\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022655\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022657\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022652\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022653\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022658\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022659\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/6/21603?source=related_link\">",
"      Ambenonium: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_29_15829="Methsuximide: Patient drug information";
var content_f15_29_15829=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Methsuximide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/54/43876?source=see_link\">",
"     see \"Methsuximide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/58/10149?source=see_link\">",
"     see \"Methsuximide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F194861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Celontin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F194862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Celontin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10922613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692054",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat seizures.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702502",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to methsuximide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow laws about driving with a seizure problem.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697875",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697880",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Arthritis-like health problem may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699037",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle or joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are worse or not the same after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696460",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. This could cause seizures. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12077 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-6BDFF69EB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_29_15829=[""].join("\n");
var outline_f15_29_15829=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194861\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194862\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10922613\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011337\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011336\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011341\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011342\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011344\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011339\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011340\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011345\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011346\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/54/43876?source=related_link\">",
"      Methsuximide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/58/10149?source=related_link\">",
"      Methsuximide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_29_15830="Quetiapine: Patient drug information";
var content_f15_29_15830=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Quetiapine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     see \"Quetiapine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      SEROquel XR&reg;;",
"     </li>",
"     <li>",
"      SEROquel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Quetiapine&reg;;",
"     </li>",
"     <li>",
"      CO Quetiapine;",
"     </li>",
"     <li>",
"      Dom-Quetiapine;",
"     </li>",
"     <li>",
"      JAMP-Quetiapine;",
"     </li>",
"     <li>",
"      Mylan-Quetiapine;",
"     </li>",
"     <li>",
"      PHL-Quetiapine;",
"     </li>",
"     <li>",
"      PMS-Quetiapine;",
"     </li>",
"     <li>",
"      PRO-Quetiapine;",
"     </li>",
"     <li>",
"      ratio-Quetiapine;",
"     </li>",
"     <li>",
"      Riva-Quetiapine;",
"     </li>",
"     <li>",
"      Sandoz-Quetiapine;",
"     </li>",
"     <li>",
"      Seroquel XR&reg;;",
"     </li>",
"     <li>",
"      Seroquel&reg;;",
"     </li>",
"     <li>",
"      Teva-Quetiapine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700570",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a higher chance of death in older adults who take this drug for mental problems caused by dementia. Most of the deaths were linked to heart disease or infection. This drug is not approved to treat mental problems caused by dementia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692186",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bipolar problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692052",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat schizophrenia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705827",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression). It may take 6 weeks to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702835",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to quetiapine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a family history of high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697268",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high cholesterol or triglyceride levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697224",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma or cataracts, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are overweight, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have Parkinson's disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every 6 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High cholesterol level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698150",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High triglyceride level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698139",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood sugar. This most often goes back to normal when drug is stopped.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness, trouble moving around, or stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, period changes. These include lots of bleeding, spotting, or bleeding between cycles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705419",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Fast release:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Long-acting products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705873",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach or with a light meal.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11010 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A20BFA4EA1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_29_15830=[""].join("\n");
var outline_f15_29_15830=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216269\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216270\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028632\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028634\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028633\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028638\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028639\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028641\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028636\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028637\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028642\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028643\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=related_link\">",
"      Quetiapine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_29_15831="Keratinization lung CA Light";
var content_f15_29_15831=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Keratinization in lung cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 318px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low magnification photomicrograph showing marked keratinization in a squamous cell carcinoma of the lung.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_29_15831=[""].join("\n");
var outline_f15_29_15831=null;
var title_f15_29_15832="EB simplex Dowling-Meara 1";
var content_f15_29_15832=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86392%7EDERM%2F86393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86392%7EDERM%2F86393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Epidermolysis bullosa simplex (EBS) of Dowling-Meara",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGwAkADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0Dxehhk2pJyTjrXGXzKY9hfLCtrxNcTyb5JOBniuTilM1wMkVwTeh7uFg27m/o0ZBXk/nXSrMEjA5J+tc/ZuEUYPar32pVXLEZrJM7akrMbes8jEkkCsDUogwPJz9a0Lu+DE7elZlxIGBJNK9zLkb1Zyuq2hBJBYfQ1jRalJaTbWdiOnWug1u5RY2yea4x8zTHAyM0xySS0OrW/MsQw59etT2N27zgZPHvXLZaFcqSMdRVrTLwfaANxBpDg7Ho1i52ABju789K0o5Gwvzkg9s1zVhMGCZJI7mtqB84K9Tzk+lQzsNZWZUUhsnqTV+AlgME7R79ayYZAPl/hq/bysVGBj3pEydkbcDYPLVchY4yMn3z0rKt2XJPJOOpq8smABjiqRyT1Lu9scGmGQ44x+dRB2/g6+9SLnGCRn6U7kpDk3sOuR9cU1gynl/yNOAHJJ5p68jHNJspFfc3uB704OcdsZp77ewyfemgLn5iB6VJSsxQ3XO40yVVAzhselS4APDFvpSOBtPbNBLKZyp+QcnvUEkbHnJ256VcPXGQwPTtUbKNuMMvOetO4WM949rHduyehziosNnO4L7E5q5IBksDkelVnRecc+1IEU5QSp2nJ96oyqy55OfUHpWrKuY8FePaqMybH6EA+lS0UZsquASrZI96qOztyXx7VpOcbtgH1qk8WSSGwD2pAVHD4yxOPc5qsxdW4Y4+tW5FIUqMcHvVRhhiRQJjXLHPzHketZUjtDISC2PrWnuHIxg1BPFvRsdaaYiHzGdQwOTWP4luFZIjt2yDuB1rUhBjOCKi1OyWeEk9RzVpsuDs0cuTIWDo5HqM1Y8xv7x/OomTy3KEYwaditXqe5ScZR5gZ2z94/nUbMxP3m/OpCtRkfNUnREAzf3m/OpkkYfxN+dRU8CkbxLKyt/eP51MsrD+I/nVIE08NQWXlmbP3j+dSLI394/nVBHqeN/ei4IupI2fvH86nV24+Y/nVOM81ZTtQaosq7f3j+dShm/vH86iQZqZVoLuh25vU/nRvb+8fzp22kK0C3Def7x/OkLse5/Ok20UCasNcsf4jUZLep/OpiDim7apHNUaI8t/eP50bm7sfzp5GKawqjilqxuW/vH86Mt6n86cF4owaZNiNtw7n86hYt/eP51ZK5qJloM5QKrls/eP51C7MP4j+dWnXmq7rzzQc1SNiMM394/nQxYrjc350mMUUGKKdyrYzk/nWRdo3Zm/Ot+Vcqc1mXUeaDmxFNNXOdnLg8M351HG7eYvzN1Hert3GKpKMSqPcUjxasOVn0t40xLiGEAY61yH2F7ZFkfvXYXkEgdpJBuOScVxPirXVWYW4TZtqpbHXRnKLsi+l6sced1RG+3k/NXLf2i83CngVIkkzdGwK53dnfBq95HQSXaqM7qy73UsBghJNMghDf6xvzqWRbSMfMV496aQ5Suc3ercXPLZx71BFAIhk9a1dS1K2RWCFfwNczeamGyAeKuzJ21ZYvJwAcdKzUuWinR19aqy3m4n5qqyXOelVyGUproep6FO9xGj4wh9K6hXwuCMHHFcL4EnDaZGN2Src57V2KSlwMHHvWUlZ2O+MuZGlbSEPkgMTwM1tQHgM2SR29K5y2coyADJH6VtQsSo3kkntRYmZrQFmfjABq/GDkgsMCsy1wGBLEmtGPDHoaaOaRajIOeSOKepIc4BP41XUZJHOF6VcjXK7hxRYi9hsb4Yh0+lTh1Axg1EEy2WGfQ+lSbcCpZQyQ5HyAZ96bgZyc+9TEZHbj1poI545pFIb/uHj6UpGVydoPrmnIH5xk/SkI+bLr+ZzQKxXkjPy5CtTJFBIGWOKsMC3Yge1RSLgYI5oGVnGAQcD0BqAqAx+Xt36GrEygjFQcrxjr607CsQOnUkge2aqyru6HIq6/Py/0qB1UOPmAHpUsZnSwKW7j6CqM8ZEnyrhR1NassbZyTkVSki5APQ1LAzpVG5mwKryxox54NXZI853AHFUnHzH25FITRRnTjngjpVcuWT/aq/MHbgnIPas+4iaM5Gdp96YWIJTjGMZ705WZkIPIqGQFRnNSwFScAiqQtmYmrW2TvUc1nL711lzArqeO1c5eQmKTjpVQlrqdmFxHJK0tivTG6048fSmN7VZ7cHcBTqYCaXNI2Q9elLTBTh0oKuOWrEbVClSL1oaGi5EatxnNUI6txGg1TL0YzVpBxVSI4q0h45phcmA4oIGKQGlpFxI2qMdakem0BID0ptOpG6VdjhqMaaSnUhpnMxKKKQkimFgqJqlyKY1BL1IXWqsgwauNVeSg55rQqtSZxTm71GTig5hWOQRVC5WrpqKZcigiaurGFdx1mOmJh9RXQXMdZM6YlXjuKR5OIpn014hYQW7yKRhRXgXjy9eS8M0fGPSvR/GWvvHayRZwOa8J17VzI7pwck1rypkx7j7fxM8DEEcirbeL228E1xLMSST3pOPSmoIfOzq5vFtwScE4qnL4kuX/jbn3rnx1parkQe0ZozarPIeWNQteOT1NVO9SIMmnZC5m92WVmkYdalj3N3qOFelXoI/apOilC51Xga7MbNBzyc16TacoDuryrw0TFqMZHcV6jYMrRR5JBPRR0Fc89z0ILlVjYs1LOM1rR8HJ6dKzLNRxzitqMJlQMkVASLdq2AOua0ICT26VSiXHIBq6gZRnJGaDCdi5AT0zyauQng8iqEGQynPFXEx2zQYtXHNgnAYkH1pBu9B9RSsOeQBTSemCeaTGkK3LDFNBYEjJFKWb1BFL/AL3AHepLsJ9WJNIQSODT1XP40dCFABpgQlSeCSBS4GPkLH2qXocAY/Gm4A6r36igCoQz5+U/nUZAHHOR3q2ykZKn8zUDAkE/yoFcqTc9BzVeRDjJwK0GQqD0GKqS5J5/lUsZSfAB5/CqcoO7OOorRkT0xVVwcEMMmpGUTjbhxyOciq0qhh90HHO7FXZ0BAx1zVdgXU7hgg0CMiRWT7ucfnVaaTzAUdBn+8BitSSA5JzkVUkiJPQYoAx9hIZWFUzmGXcvIrYmiIbjKkdDVG7DAnI5PXjimmSyaCZJlAbAzWfqduGJyuR2xSD92xwPlNWg4kiwTzVCOVuEKSFfSoTkda2dTtQMtnmsU5yc9qpO56+AxN/ckOoxSA5FSDmmestRnepB0pdtGKCx6VMlQrUy0DWhNHVuI1TQ1ZjagLl6I4qyjVRjbOKsq1MpO5aUmnH3qFHp5bIpG0UK1NyKQmo80BNkuc0Gmg0pOa0PPqMaaBSgZpwHrQYjaY4qbApjigtEJ4puae1RmgylqIahk6VITxUTnINBnKJWeoWqZ6hYZpnJONhKUgEU0cDFOBzQRe5UuEB6VlXEfzrx3rdkTNZ88f71fqKRyYinfYt+PNTZmcZOOa8tuyXkLHvXpPjlAXbAzya87nj5zW5xqPumeRikxU0i4qE5BqkZtWEpRRQKZId6miHTimKvNW4UHFJsuEblm3jzitOCKq9snStOBKzbPUoQLGn/ALq4jYdQcZr0nS23xKzY4GcV50igciu50mUPDGo9BWUzeqrWsdZp+1ocg4bPQity3GFU4zWHYkBgD6dK3oHAA7VmYSbZoRAcYP4VYUHPOagiJ2g8A1ZDEADcKGZON2TwjgZIHarQYjkciq8RJVfmFTKTtwKVyGmTbg3Y4pgJCkEGmMuRkg5+tM5zn5qTY4olyMYAwRQzvjjHNNfAGCDmmsyhcA896RaVyZTyAcinkZOSRiqqyYI2k1PuJGc/nTCUbDjkPjNByeGHA9KAcjkj60mAfoKCSJicnacCos5zyc/SpTkkhRk1XlbB5AB9qBRQkrbgSarSsMcinSAFsZNQu23g8D2pFWInXqQBUDgHrzVlielQNwxz2qWNIpzqfSqzKCdwPGMfWr7YyQ1U5FVWJUcenpSBog25GO1V7iHIC7cmrIIJ3DPFKVD43ZJPSgkxZosDnGR6Gs65XOeODXRywrkh15z1rMu7Y87emTiglnPNjlabtaM/LT76NomBx0PNR8PgqfrViCYrcRkfxYrnbyIo5I/GtyXKMWUYqreKZYMooz3poUJuEudGOh5xU8dVlYByD1qynSqPp8LWVaCaJsUYFA6UUHWIBg1KtMxTxxQA8HFSo1Q09TQQXI2q0jZqhG1WUegumWlPvTyfequ/mnBjmg6U7FjNOAqFDiplNNGNSVhaUUE8UhNWccmmOHFLmo803fQTZE27FMZ6jL1Gz0DSEZqbmmMabmgXKOJ5qNzxTs1G1BnKJE9REd6lcUwjimc1SJEetC9cUpHekUc0HNYceagdMyDjuKsCjAMi/UUESVzM1y5S5hf+9k1xF3HtY+lbN3Mxd8dCTWbcfP1FbJ3OeVLlMiVarutXpl+bFV5F5qkcdRWKxHFKq5qTbmpFShmSVxqJzV2CPpTIo/arkKYNSddGndli3GK0ouKpxDFW0OKhnfB8pZB4rsNLcq0O1eNoxXDNKACDXX+EZzPGruuSgAAqJrQirUuzu7IMrKQO2Sa3I3JT7uc1k2xaNVLY+boua2YsEgLyP5VkSncvQZKZP3hVpWyRx7VUjGwZzwatRZxx60DaL0eAo46VYUjbVaPJPOTUhIBxnioMmrsc7eg5pgcfxZzSOV2ng/Wm7vlwpzQUokksgAznJ7VRmu0DN+lMu52O8L2HWsC5vG3bSNoGct61MpWOujQ5jSfUCjYzVy11NWX5jXGzXoBwz5J5yanS92HYh3Z6YqOc6pYWLO3hvI5GwGA/GrDTLjOeK41SVi8xWIcHGByKsnVWSHbIMt79qrmOeWDb+A35ZjgnIxVSe5AxycVlQags7YD5PT6VK7dhyelPmGsK4fEXPtQK5GOe9KJlIwSMnpWXKwAI6nvUUUzKeOgouEsLdXRsoc96GAJbIzVKC4+fB79M1aVyAeePei9zinTcWVZ128jpVZ2Azmr8i7h04qjcwtnPIB9KCbFZW4bbTeR71Cu9JCD+YqSNuCC3U8CkTIlGHU+/c1TliLE/pVorx9459KjXOfQemaZBhahany2B+90Nc+VNvIV5wa7e6TcjcZGPyrm7y2DHIPODzQKxQGG61Wkj8t/9k1O3yNjn2p7FSvP51QrGFqFmQd8fJqtA5xh+DXRNGCp4yKytQtCpMkQ+tUjowuKlh5eRGuacAc1HbvvAH8XerIXimfTQqRmlKOwzFLT9tG2gOa4lGaAKXFArXY9TUytVbOKduoNoKxbVxmnhuaqI9Sq/NBUpFtWqeNqoq/vVhGq0c85XLe6msahDHHWlDUzEVm9KYSc0pNNIoGhGJpuaU9abQUhppuTTqbSYxKQ0UUricboa3So8VKaaeDTRzVIkLCkAIqUjNM6VRxyiJSr99frRQPvr9RQYyOHufvv9aoy9avXH32+tU5BmtUZTZSkHNROuatstRMtUcUldlcR81KqUvTpRuxQSmokyjFTxttqiJsd6Xz8d6OUr6wo7Gl5uOaGueOtZbT+9Rvc+tVymc8YaEtz1ruPh9OZYBjO3cQa8ukuB616P8LnU2E5JORJms6sbImhifaVOU9UtJjKUJxhQFFblu3OF5PpXOacwaR9xAwRz2rctBhmyc81ynpxNWMlgN3QdKvQHJPXJrPt/vAn9Kvxdcjv3oGy4gKgdetObrTEB2YJ5pC20ndWbItdiOeD2pocAdRiqtzP5aMxJI9PWsk3sjSHcPl6cdKnqdcKLkrmpdeWcqRkHmuD1rUDbXMkZYEZOF71v65qaWNnJ5s6JIV3cnp6CvIbnWLo6zPcT27TQA4KjkrkZJ/Kq5HPY0jWjQ1mb11rkYJTy/r7UkWvfZ9smCqj+KuR1VJre9t/7NmaeG7HmQb//AEE+9Lpd3IsbJeJlmLH5hnH0odGUY3NKeY0pyUUe1+G72KW0hcDewIYe1R6rE89xI5Mauedu79K4e01q806BDZD5pl+VSRwazL3XL+fUTHZmN2QAmTqFPeiMOZcpTqKlPnO3DPBhwMYPIrordvMt436FhXI6Lfx3VlFDdDMjtnzB612VmgEAUEHHTNLk5dDoqVlVimh4iBHqe3FV2i2knGTWnGr7duB9KbOqhCwK574otc5+exl7WXJz36VbgkLA7u/FQMUG47uvvUtlyrAckc0rWMq8bq5YfnBWlI3Yzn8aFXgChxhhkcUzga0KU0CAlsc1UaLYQccE5rUkA2sMgGq0iMT1DKB6UGZT3c456/hQVBY84x6U8xgE7Onp6/SheBg8UCaIJgMfKPx9ay7uFih/2jW1OgOMDPvVWZRkgLxjIoBHKXcGCynr2qs0UmzIAwK3LuDeMj73pWc6spxQKUSnBICCG6Ci4TIJj6Y5ouEZXEiL8vUgVLEdyZTBTvVEPY56aLy5DInrzVmFw68dKlvlUbigI9aoxP5bZH3atHbgsU6b5JbF0dKaaVWDDIpG5pnvRV9UNoNGcU0tzSOiKsgY4pN1MZs00nigluzJQ3PWpFbnrVQGnoaCZSLyNUytVJGqdWpmZbR6fuqsG4p4biqFylpTmhqiDU4tQANUdOY5pmaGUlcKD0oyKKkdrDaKdSN0oBjSM0hGKdRiqRhKJERzSbalK+lG2qOSpEgZajH+sX61YcVAR+8X6ig5ZRscDcSjzH57mqrSe9Vbi4/ev9TUDT5710qJ4s8VfqW2k96iaSqzTVG0uapROeWIJ2kxUTTe9V2kNRliaaiYSrssNLTTKexqDmjmq5TCVVslMrYphkJ602jFFiHJsDk13fwzujHJcwE4yVbHtXCjrW74LlaLX4QDxICD+VRVScDowkuWqme/aP8A6gv8hI+bDHqK37D5u/3snHpXKaM3mTRgjKKMda66wXIAwBnpXnn0iNW2xgZGavQAH+lU7cYAB61ch6HsaTYmyYnDAGmMSc5pDyRk0MjEdTUMEZepKDCwXczEHvVGwhaXTpGOTJ06dBWtdLuiZdnT0707To4440llkjjReCvrRBXZ3xnyUjiPGWjPrNhamJkE8KtsYrw+P7wryyaC/hu44JbSS0uW+71Pm57Y7ivoK8to3lIRlkt2GcYxg+xqs+nPBt8lEuYYVDbZQGYH1U9R9K2hJw2OOvShWV3ueGeMtOuNBGmadd7kvoJBKVUcIH5ABqaS1xMXZmabdklu6+9epeLIhrqAzxByoz85+bI6V55crbadKsFwT+8bIYnIP+zVe0T90544dwkqnYbFPbQwF7jlgyiNSMdarXFoZbpra0bckpBlmBwWGPuim6nNb3OoKsblYMHZv44A6Vd0C6BUKYyyPJ98ngegqY+7qjaVVVZcjOs8I6bbkLBMjLLGQdrnkDtXZ+SkQcnJDdwOlcZaIwuQ+nJiV/Q5C4ruWAfSWmQ7pkXEoHQe9ZOSk2dkE6ajFvQyrq8kkfEWR2IFQi8aIEXLbYwCefSrmlQRs7eZkuTgBRmsrUIh/aTQ3MgVWyAG6fSspXWp6cORvkaOR1PWpry92WjMiA4B9a2vC+syrdrbXud/TPf8azr7SYUnkW0nQsByc4A+lT6NZzPqyvMylxydpzUq+511IU50tuh6OTuCnHPtTZhUtqpMIGOTzmnTRkLwRWl7ny81Z2M9xgZPXvUHJOCCBVmZSD1GahZQTgscgUyCNVHzL1IqCRMA5JBq2Spb5RyF5pJF3ICVz2pCKTH5VBPJ6VDMvAAO3tmrTJsz8vTgE1G0bEHIznkZoIM1hxz0PU4qheWjMN8a5OMECteWMgYwQo559Kh8wrlO3Q4pgzmmYKNnUE00KYX3x8qeorU1TTzgSQqNrDnFZdvOInEcnQHvVbkPQS8tkmh3xcE8sK55UIuSjDgnvXXvFjLKDz+VY2p2bqvnIOQetCaTE43V0UMNE2O1LuqyoWeLPcdarMhibJ6VZ6+BxlvcmIetNNKOaD0oPbctNCE0lSbaQrQYuRGaVTTttJs5zTJJYzipkNQIKmWgCYEmng1GlPUc0FXuSqTxUgJqIVIKAsITzSU4jNNxzQWgAzT6RRin45oExDTSKeelIRQIjIxRinEZoAxVIzmgHApcUlOFM5JojfGDVZvvr9RVmTgGqpP7xfqKZyVDxieUmVz7motxpZf9Y/1NJXfY+JbbHbjSAmkpc0rEiUUUU0UgoopQOKYrCU7FGBS0BYaOtX9Ek8nVrN84xKKogU8EoQ44KkEVm1dWNIO0kz6I8NxidEycck4rs7b5SEUcgdc1w/gy4YadbnaC5QfMe9dpZ5DqQOvf1rz/AEPqIu6TNi3AG0rknvVpScioLY4BPpViMZBz1rNksm7jmkznjNKO3pTJMIx7DPU1LZSRUvm2ttU4B6miwktsbLhVO49+3vUcsoafPGE5yehrJgWOO7Ms14hYDKrk4xnPpTV+h2XXLZnQC1kklIEsapn5QCQP1qs72kOsrZSX6I5HzIx+ZgemKfHIbm3E4kHtkjHtXnnj+2kuriO/jZobhBwUXdg+2ORVtmEU5Plbsdn9kjae5MkvlCHIG/8Ai9q5Lxn4ftn09ph9+L5zx6+lXvB19JqVkVvbyO4uU+SRWOJNnYke1X7mZZoJbcIdjDY6ntUt9RcsoT5d0eSanYo8ttatbyec0YZSW4DHsfajRjfWt+sd23kI8wTYcFcA8/hW7qdndQ3XzBXdT8r54ZR0qbTtKGq3sMk6ZZTkgDAX0FUquljX6neXP0Ox8M2vm/6TLHhH4QdM81sancstpJFbRwxK/Du3AH1pFKW1ikDON0Z+XaO1U9RkiksMSrL5UgK8Llifp3pStY6aVNOWpm6Trxs0uJraFryZXyY1kCkJj7wHcVnavqCa5NBvthaQBvNlmL7mUD0HXuKmTTxfpb5je3vLf92Z1JG5R0yK0ItGZpN11KkgJyWZecVN9LI7eSKlz3szEg0aeS6Z57hZrXZwcYLV1mh6dFGv7qPbkYJ71dtbOJU+dMqBtUGtbTrYQZUDNJQM8RjG42GRwhFUZPAxSzL8o9fSrpj+U/Wo5VJYcCnY8WTuzGnjUscjB7VUQhiRnnpmta4i+8WrMkRUViATSEQuGQgswxmnRujMcnP0qV9rR8jjFZylkdto3qeOOopBYtSxh1zyAKiUAqRuB9KnRxIvAxt6g03AYr0B9hQQ1YrSJ5hLHO7HBqq0QCbe4/WtVVAPzHIqJoupIx6fWgRnrhFWFjgE5Ga57X9NJBmiUg57V1EsJ25+85qruWTzElVRxijYNzltKvDNiKTiVeCDWjd2+5eMEEcisvXbJrKeO6hwFz82K2tNdbmJGzncKrczehzKoLW7ZX+6/H41NdQb4jxzV3VbTIJ7g8VXtG8yIhvvDqKpMpXTujEB2nB60/Ge1W9RtTu3oKqpjoetUe/hMT7WPK9xu2jbmpCKUCmdGpCUpVQmpsU5QMUXAiVOaeFxT1FPwKAuNUc04DFLRQCaFFSCmqBTxQUpIXFGKcBxS0FpjcUpFPptANjaAM0pFKBQSxNtJipVHWgjFUjKTIyOKYTipGPFROaZzyIpDUBHzg+4qVzUY5dfqKZyVFc8Um/1r/U02ny/61/qaZXoHw9gooooCwUUUoGaBiU5elKBiilcAopaXFFwEA5p23seh4oxingZGPWkNOzue+eB9kmmxrF8wjRc+1dtZOfLO7lV4X8+teT/AAq1CZNNmAcgl/LPfIr1C0lRY8YxjGc+tebJct0fT0Zc0E0dFb52gY4q2vB6f/WqlbOc/eFXIzzknOayY5LUkLYHNZN7dgShOo71ozuoQ9mFYc6LJehOcEct6GpOvDwT1Y3V7uGy0ZZGDGWdgn+6PWsLV9aS2tgttHIttH8uQVLDj355rrb6ytXsUM4Y+XznscVy2rWFrdW0v2eYs7gMyEZxT2Zq+VppHEQa9qWmysDv2SNuCMAzY+orVh8RNczhivlXirtAIx5g9/cVd8P6NOkFzbzLFOyjAxwQPQVFr2mrbxRzIQpjf7rEcfjVylbVEqEKkuVsueG7A22oPM0MnnOp3uOh5z0rprbT5pJt0sZSKfcySAZBI7H3qvpckqWkX2mMByOvSrHh283apdaXM7hDi6hZTypxzj24qYO71MK7t8PQgltbYrOsq4lXHPqKr2gjhYi2XDMMZ9K0tTmsJlWe1uYzJMxzHyGHPcdqr2kS+W0gUZJ457UNWkb4WV4XbIlufLu1Z1yU5x61b1OYX5i+zOYrlOVZD8q//XqOaz8w7u+Kns4ygAbgfxfWlqeg1Cykt0T2lukMDffaRjl2JyWNWHi4Bk4J6CgKSQwwD6VKgCyElcsemTVmEpO9yezh34LnCjtWnGUUbRVCGRl3BcCpULYVm5J70HFUu3qWWIUEdaa4BXjNIp555pXyRx+VBi42K06Bx8vBFZtwoMowRWox3NtzjPaqrxqGYjAxxg1L1EkVJFBO3Ycms68hYZYgLj0rWZV4bdzUUyR7XD4JPTipZdjBhuNkhG7PqGq2kwZQ6kEDsBzUF5bhWWRVJGMH3qNJQVyQwA4pCcbmgj7iMAAEdKfkOBn71Z8UqbiA2V7Vet2BwB1IqlqYtWEljynIye2KzbqMCRSynjhq2WU9F5x61TnjXeXwSvQ/WhoEYeoW6XNoygZIyPrWDokrWty0EnG08A+ldLOvlSMp4x0rnNUiWK+S5jHfBxTixSjc25oRLbqVAJJNc7JEbW4Z8cE4aumsHDxoueoNU9StQVIC53U0SjMkVZYsg8GsOeMxTH0rajBjYwuBj+Gqt7DuBqkbUajpzTM8GnGox8uRShs9aZ9JFqSTJAMil4FR7qN1K4WJQ2KN1QlqTdVXIasThuacDk1X3U9GoM27FlTUgHFQI1WF5oBMcOlLQR6UUGikLRikooK5xcU8CgClp2IlIQ0wnjmnOcVA7UzGTB2qJqC1NNMzeoxqRF+dfrT9tOjX51+tBnNHh03+uf6mo6km/wBa/wBTUdeifBNi0o60lKOtAIdRQDSigBKUdKWipYCU5VpKkUUAIvQ1Ig6cUgXin9qTA6/wHfixS6LNwuGwa9T8Man9t09LgkkgkkEYA9K8N0t8ebGTtLrgGvZfh3aiw8MJLcSBo7vlE35bg8k+nSuKvGzufQ4CqnSO/wBLkd1JxwOea24ywAyAKw7O53tGSNpP3B7e9blvtlhBGc55rndmd0tdSvfOVXc1ZS7kt1mYcOSc1q36bomwOAeKzYVc25hPIXlQfWoOmlpE1phFdaeI5mCgrxisg28NpZSlAWRVw3Gc1IwuRGsbhWBG7OeKIoJHtmCKQrZyC+AfwpNti5FF3bOPWIrPzLLGhbKpj5gT05ov4ri6vIzIiQ28h2l2AO0jqfrW/d2whn/fZZ2XIVVB/Wmy6X5kLQLJ5azEsu3rn15pJtaCnFRlzRI5L2BoEhiL+ZDgeYejgd6gtpvK123uYHCyBCA/oCec+3tSS6eLaNI924A4wT0HrVGaLy7qIMx254NVF+8KdP8Adjb4/Z7iOVcEmXJIH9PSuosZFMHoTzXO6yuLRZ07HmrumzZUEdccVpLe5nS+Gx11vHHLFvUY29c1EIwS20Zyc1UtbnJG3uMe1TrKyjYCDk9qNDWE2mS52HAPOelTHci7+CagJBwBjd609CxKiU4HTNIuUy7GkZiDMNzZyQDVzz7ciNAm3IxWawMALA8kVFa3uxJC/JPT5ec0pTUXqc7hKb0L7cOeePUcUskzcIpAY9MCqlrO06M7EAk4wamQBS0hOccCi6auh8pGzNG7BuvXNN85TneMk+lVZ55GJxg59ajjdwSpABHWpU77GipaFxo8rkDFQhQGJY5Jq0hVowc0SxrtBAoMmZ1zGCHTbkHoax5ojGSCCG67TW/cAhflGc8j2rNnjV2Bk2lu/NIRiAlHO9eNxxWnbSD5SMis+/j2oxUg45yaWyuNx29l700ZyR0cXJXpUMgOMjqxzip7VcqCCMgZqWSHuMAdRVNGaMC9hYlsDJPX2rA1GPfC6kZPXiuunhLZ5+Y9axLu3GCB64+tTezHa5l6NOSm08Onyn6VttGs0a1yszmy1BJQoEZOGz3rqrGYcdCpGc1ZFrGHqliShKffXnNZIfzgQ33hwa7m6h3qcAYIrkNWs2tp/NQfIeoFNMTMC8Ty5OKrb8VoakQ0YZRzWOG9etWe1gKvNGzLIkpd9Vt1ORqlo9NSTLIajNQqTmnAk0xOzJRTgcU0dKKZlKOhOj1bifIrOUlTViNzQY7Mvg5FDVCr0/fTQ7hQOtA5ozTsFx4PNODVCXpvmGgmUh7tUDt7UrH0ppOaZk9QHSlWkp6igaFVaFH7xfrTqaThxz3oCdrHhUpxI/1NMp03+tf6mkHSvRPz3cMUUZozQMVetOpoOKUGgB9OApop46VLANtPUUlOXrQAo5qRRSKKlUYFINh0RKuCM8eleveEAq6LpbBm8tiVIbnpg/zzXkK9a9H8JX3naGLbcMxsCuOorlxV0rnrZXZycTu4ry7n14CQhY1baMcYArvrJsghD16ZrzNriWecXMfEUhKow9utdrpN+otYTu6Lg158Ja2Po5xUo3RvXCblZfpWbNDKJFki+8Ooq/bXPmbBtJYgk06VA+Sp2tj1qjKL5dGZ8czOSLlDkDAIHFX4JosJ+6X5OvPWqwzs4II7g9c1GJEUFcYNF7msoqaLvkLLiXCrjjFVb21lmmg84KoiJIZeMD0q0kkbRoqYJPU1ZMZaDMrKTg5A7VTjdHK247nOalbrHbvyCw5rnb5VMcMrdQ2ADXU6mFa3fG3aOOetc1qcS/YG2AkDBzUW5ZHRF80NSjfTKNKIOMscDP1qzp42wxsT2xXP6hchbZY93LEbQa27Rt0CLnnrn0rXcxg7KyNbzvLZUZsH1rRglQRjbyfWuU1G4dFBYElTnIqxY6iGiGCfUVLVh3OrjkBZfWru7KZGDiucivP36Ov3COc1qi5GVIPBqefUtM143XyX34ds8e1Z906qIgPlZSTn1qql4Crc4GcdadIPOPJzjkGlO0loOEWndmhE37uPy9oCHuec1Re4mbztis53Y4PSnSyx20BaRN2Rxz0NU9Puii7OA27czeorHmt7rOiMHZs2ISjwrC64ft/9enDBcqB160sMiSyny2Bb0pY0KzNkHgcmtYoxuOjVUGO3vSTzhBjj8KVnUHBI24zWZePIQCqgD1qpaEqF3qWmfn13fpVe7TdjZ8x+lNtW5UE81bYDHJx9BSInHlMG4jAG3BHHXHFYMrNa3G8AiNjgkf4V2E0ZbO4Db2B71gaxYqVZ1yoxxzVIxep0WkMJIFIOQeh9a05kJYDGOK5PwZeg/wCjueYz3612zIDk5BY/pWlzB3TM2WJR061kX9vhGx1PT610Mkec89vSqdzECMsMen1qWjRHD6pYiSMq69BVPw9eMk7WMzfOnMef4hXV3ttgt5n3j2rkda014nE8DMsyHcrCkQzsYJA6YOM1W1GxSSFlIySOazdF1AXMQbOJFGHU9Qa6AMssZI54qiWeW63btauVGdnvWKBmvQ/E1gJIWyvbrXAMjRsVIxjpVJnbgpJSGYxQOKfj1oxV2PVUmKpp60xRTwKLFXZIp4pc00cUoNSaJ3FJNORjTKUdaaMpFpXNSq1VVNSK1Mi5aVqCwxUAYjvQz0yJSHM1Nye9Rls0ooIvdkg5p4FEYqULxQaJaEYXnNOAxT8YprMFoBuwhIFU55cOOe4pbiYDoayLm5/eAZ70zir11FHlco/ev9TTafN/rX+pqOvQPiQpcUlLQAU7FIOtOoAUGng0wU4VLAkHNPUc5qNTUimgCVTUyioUqZKQxwAzXWeCmjU7VlG5sqwPG30rlsA1YsJ/s11HLyQp5FZ1Y80bHRhansqiketLqqW+m/ZRgRAljkflg1p6NqSSwsocGP8Aix61xizxXcKW0oYhiMSK3QfSmwxNZ3WYHkC7uVPOfrXkyjY+0ocslY9k0q5aRFGeCe57VtB8kYIGfSuR8JyyPaRPIpAOeTXWJjdkAbRxVrYyqK0rEcmVR2BGSaybd/N1Tynyy+gNalwMqSCeTkCsHzHtdSE2MZ4qY/FqaRV4u2509xp5to3ljOBjIG6q8V6zW0sbAeYmVyTyfpVO68QDbuyZFACgCsvWPtF9Fbz2csdo+8t85JJX0/Ot5WWsTi5ZStzjrubbC6yt8/TAPeoLiNpLA528rnpVOHT5ZL0tO3Ug5I6mty5iAtFC57g1z6t3OycVCmlF7nls2VncyHPltgcdK2LXVY41UEqQffpXB/EPVLnS9WltYeBIN++uGuNWv5Rh7qQDp8pxXZCk5K54lfHQoycbHteu+IrG0tm864UDHIHUVwknxChhMcVrZMI1P7yXzCS3PUCvPpneRt0jM7erHNRknv8A/qreNBdTz6mYzk/3asfRvh7XrbUbOOaCQOh7Z6V0sd8jIACBu6c18uaRrN7pE3mWUpGeqHkGut8MePLtdWj/ALQdPIYbcheFPrWFTDW1R6NDMacmoy3PdLIM98wYEr19q6e3hATAAxXJeG7hp0EjHIPf1FdfbyAj0rkjGx6s59itfRBoyO1VLK3GSr4KrzitaZQ64rOmiZcMpwelZzim7nXCTcOVF/8AeRxqYQgXGSR1FN+0IY92WOeOT3psBW3TfM/yMOB71CPMdyUC7W5HHSk7oxVMngiLzgjge9X57RjHtVR68inabaHeJJeT2rWlI8s7iMV0QjdXZy16nvJROSMJiuOvHtV9V/d7gOKWdN938nT1qcIu3GKllzd0rlKVfkKgc44rGvrdnY5+UAdO1dI6DgY6iqF0mEJ6ilcxOMnZrK8S8Q/d6heM13ujahFdwKUbKtz+NclqduHXLDao9KraDePpl8sUvFvI3yn+6a0jIzmj0gx7zwBVaaNcEHr3qa0nWaPg846CnsjEgYwT3qmupCfQyJrcEAsMgetY9/ZiTIPQfrXVSxhuD2qlPbgfw5qGB5xe2smn3RuLU/e4kXH3hW1p2oLJErKflNamo2glQjGT2rkZAdNut4z5EhwR2U0J3FY6LUAtxbkEZrzvxBZ+TOXUcV2wnyAOobuDWRr9r51q5Uc9arqOnPkkmcWop4GBSopBIIwQcVKqZrS579O0kmRqKcBmpQmKcEAouacpFj2pCKm20hUUitiLFApzHaaZupozk0SBsCgMKgL80m/3qjCTLXmUBsiqwbNTLQRuSgVIgpqDipkFBaRLGKlAxTEFShSTQNy5SOThTVG5lwOavzqQprF1AlQaLHFiMQlsULy5xnmsa4uMyrg9xT7+Trz1rK3EzL9RV2PCxOJcjmZf9a/1NR1JN/rn+pqOu48ZBQKKWgYq9aeKYKeOlABRRQalgOXrUkZ5qEdakWgC0lTLVZGqZGpATg0vHHPOeKj3c08HNIr0Ol0HUZ4bF44Qh80eUWPVT1yK6a0uGmt/IJIk4O49WFcLoThb5I2OBJ0+vautilmDL5cLZB2niuGvHlZ9Xllb2sFfdHoPgfzY2MbvlAD8p6D6e9d/b5wNuAF4rzrwpHdBi8iFQ3bPWvRLXHlfxVitjtxD964s0RbGcjHSs66sVmb95kjtmtjIbFL5eNoAzxUGcKvKc+NPjU/dHtkU6y8iG42yxI5A5J+tbM8YII2nPtWPPaSkkxj5veqTsbaVFZle7kUX67MBQexyKuzJviKoMsV596px2E8kheT+9nGMVssNlv8AKvzY61N7u46sYxikj56+M1hIt9b3JiOFXy5HA4B7V5i2K+lviFpS3+j3cKry6kr9etfNkoIJB6gkN9RXfhpc0eU+WzSk41OfuV2FMYDFSN1qNutdJ5Y2gEryDjHP40GikC01PePhjryX2mxlnxNFhJF9a9RsLlZAuSMV8l+HdZuNEv1uICSnR0zwwr3Twp4rttRtlaCUZ/iUnkVw1qbi79D6PB4lVoqMtz1DzVPQiop03ISKxrS+8zHzCtW3l835e3euVnrQnyFfazTL5jdOgq6jA8McY705oVJBqRIVH1qFHU6HUUlcsW1wUUBJCWqcytL941BBbKgyQCferQVVACgfhWy0Ryz5b6CbACMAUpAXoMVPt+UZFMK/N81Iy5rkJXIBaq00Q5GDg1fK+nWoJMtkZzjrSI5TDu4lKkMv4VhX1msoKsPl7109ymW4O4Y6+lZVxHk8DntSvYhxDwrqjx/6HMWMifdY/wAQ/wAa7SN1kjBDZX+deX3kDpIJIyUkXJDDsa6nw7q/2u1/eZWVcCQeh9a2i7oxcdTp2HOfWoJVqyjbtuPmP96lkQU2rgmY9xCCDiuY1exDxFZAMkHOO4rspYjtOOuayr2EnPT3qLWLSujgLF3tZvsc/wB08xn29KuXEgaJk/CjxJZ4XzIxtkHIb3qla3IuLcFhiQcMPemZSVjm50AunXHU8UqrxwKdrP7u5VhxzTA+RmqPbwVXmhyjsUNxTd9NeTig7RS3FRM+KjeWomkxVGUpD3eoi9RM2SajLHNUYylcm3ZppbmmA8U5RmgyerJkqxH1FVlq3H1oLSsWo6nQVWjODVyFCxFA5SSV2SwqSauRW5NSWttntmtWG29sVcY3POxGKstDEuICENc5qkeN2a7m6t8A/SuT1mParUzyKtaUjhr9fmNZy/6xfqK09R++1Zw/1i/UUjhkcvN/rX+pqOppRiR/qaiPWu45RKKKKAFHWlyKbRQA+img4pcipAdTlpoOacppgTKalVqgU1ItICwpzUq9RUEdTpQUSJkMCCQw5Br1zwLcLqOnqTtMi4Bz1ryVa7H4cX32fVHhZsK4yM+tc9eF43PQy+s6c+W+57fp9sg2heD6YrYjbaFUZ+tZemSh4Q33gPWtFX3Bc8ZHFefe6Pb522WkxkcU+ThgQSB7VQgncBlcc9vpVpG3LlqCrjky5OOme5pTExPanxDrjpUu3oRQaKdiJIMnO6kkjVSB1yDknpVlMcgf/qqOcE5YD5W4xQTKTZyuuwAKVPIPA9xXzN4307+zfEV3FgBXPmLj3r6p1WImMhl+bsa8E+MGn7J4LpV5B8sn1rfDy5ZnBj6fPRv2PLmFRMKssKhIrvPnSE0U4ikoASremajc6ZcrPaSMjg9B0P1HeqlJkUNXKjJxd47nsng3x3Fe/ubsiG4HQE8N9DXqOjaiHVSzcnnFfJakqwIyCOhB5FeheB/HUtnLHbapISh+VZT2+tcdXD296J7eDzHm92qfR6XSjABzmtG22nBBwTXBWWqpLJEwcFCMgg8GupsrtZMEEcehrkem57Kaa0NvhR1596swlFAx1qpbOrjPrVqOTgAA5poznsTMcmm7R71ICSORRgVXKZXGbB71HIgyeKs4qJ93Uc0MEzLnixG4UZzWbPb/ACkDAKjt0roXQEEdjWdcQ7VdWGT71ny2KbOemgBXa61jB30y9FxFnaDh0B++tdRcRgMox+VZupWe5SyqCp9RTWhnszp9GvkmtomjO6JujZ61rkhgfzFeZ6LenT74wSgeRKRg/wBxq9BsJvNQAnp3rZO5EkW3TcDWbdRcEkdeua1uCgqrOMZHY8YoaEmclqdtujYkDpgDGc1xN5CdPvA5HySnDAdvevTL6Lg7uPSuN8Q2odGUDrWdrMJanK67D5qArzjnNYsEhCbW6itpTmCWNj8yZHPpWCv32+taI6ME2qlkT+YPWms+ajoxTPY5hHNRMealIppXirIkrkBGTRipStJtoIcRqLUqrSKtSKBmgm1hygVPCDmmIuelX7WDOMimlcznUUUPtoS1bNrb9MimWluMDitm3iAA4q4xPNr4hvREtpbgAVeWMLTI2CdulNluQAea0OCXNMr35UKeO1cVrrcGul1G6GCS1chq8u7dUSQ1R0OR1AZdqzwP3y/UVqXi5LY71QKESL9RUnHVhY5OfiV/qaixU84zK/1NRba7jgGYoIp+KaelADaM0GkoAWigUUAOWnLTc8U5amwEoqRaiWpVoAnj4qdDUCVKtIZOD2q7pVw1rqEEy/wOBVBalXOamSurFwk4PmXQ+ifDl2JoI23A7hnArpEcMBxzXmPw01H7RYoGPzx/LXpcRwgJ5fv7V5k1yux9HCV0miYDHXjA5NTwyA8DmqwAK5boe1WIVAwAOtSbX7l5OQMjOalA4wOKjTC4BqbIoC43DDoRSMGKcYPfBqRuPpUQwTweBTuUmZ1+gI7e+a8i+LNkZdEnOOYzuH4f/Wr2a6XKt37VwPjK0+0W00MgBDAgj14qlpK5FSKlBxPmZlqFhir9xEYp5YiMFGIqq6816aeh8rJcsmiqwqJhU7jFREcUEjKTFLjiimAUlLRQxo6Lw34rvdGcIWM1r3jY8j6V634P8eWN6fLWUo4GdknBrwLFTWjeXOrkn5TkVjUoxmrnfhsfOk0nqfYmlaikrfKw6dc1vW8u8Ak15F8N9SGo6NDcMB5jZBA9uK9Q02YMqquM46V57jZ2PolNTjzI2kK5wTUowR0qsDkAgDmp1YYxxVpmckSjihgMGo92Pf6U8FsjiixD0IjGCpABx61Sukwh4rRUdc9aguFwp96gdzEljYZbGPrVKYbo8bc5rXuEySPWs+5XYRjj1oQM5rVLMSq4IKkdxW34Z1UyReVMQJ4jhvcetQXDI3GRkjpWXcf6DcLdQYBT749R6UKRLXc9IhnDx8HrRMQQOaxNK1BJYUeNsxuMitcNvQkHIxWl7mdrFO4XdkHtXNa1BvVto7V1Uw/d++M1j38KlGJ5PakwR5NqhMFw7LnOPmHrWVGuAT681v68hTUSrD74wBWOsZXKsMMD0pxOzApe1aIse1GBUpGBTdvvVHrNJDMD0oIp+KaRzVEMYVpuKkNAoJlKyGqtTQxlj0p0UeavW8YGOKpRucdWrZaCW8Ge1attDjHFQx7VqyswA61oonmzqOTL8Hy46VZ88KByKxWuwD1qCW+96ZnGk5bm3NeD+9VGe+GCM5rGlvSeM1WaVnNM7IYdLcuXl3vBFZFxl81cWIsc08WxPakTVtE52aA91rPkhxIvHcV1c9p7VlXMG1xkd6zkeTWPNJT+8f6moj1qWX/Wv9TTCK7jyiOmtTsGkPNADDSU4jikxQACiiigAp6mmU5aAJlNSrxUK1KDxUgTKamRqrgmpUJpAWFPNSqagU81IDigdzs/hzqH2XVjEx+WQbh+Fe26fKzRo553CvmmxuHt7mOZeCpHSvftAvVudOgkjbKsBj8q4MRCzue3gKnNTs90dGsqkkbgCOxqaG4BICgkj2qrbojMM4JrQhCqRjGMVzHoEqTvjO05NSrcOcblIpIphtUnFTo4J5GRQUrCCfdwQacCM/KaeApHSopUUYIJ9xS1K0CTlDuxk+lc14kt1aEnAOK6IqSeKzNVXzLdhxkA5FXck+X/ABhafZdfukAwCQ4/Gufccmu5+JkWzXgMc7BmuMdPSvRpO8EfNYuKjVcSg461C2atyKRmqzCtDnIW6U2nN1pMUCEopcUlABmlFJRTDU9D+EWvfYtUOnTPtimOYyezelfQ2lTY2sOoFfHVvM8EySRkh1OVI9RX0n8PfEC6rpNvISN5XDjPIIrixENbo97LcRz03TfQ9Qhk3c5q2p+XhayLR8jg9RnNaET5HFYHp7ltc4yvAqbP+1UAcEYFPTCnkZzVXMpIlzjpzUM43YAzmplBJzxzTXB+ZgcUrE3M+45OVB+Uc5rOuBuOGHUVq3O7axxWTMzMcAc+tQ9DRRuZUkSQSMWGR2qC52XMeQuQDluK1JLMGLJOX9DWPdtJBu2xE4649KVirJ6EWly/YJzCz/uJTlWxwD6V1mnXQxtJrhZyZLchv97HpWvol8ZbWKTOSBtP1FXF3MXE7CVg2PSs24GQ3HBqSCfem7tSXGPK64yciqaJseZ+LYnS+jfHTnI7Vz1xMHmVm4Zlwa9H1m1jYMzgsx4zXn+tWwgKMgJ2nmoT1NaU+WaZWYHFMxUuQwBHQ81C5wfatbHryn1EJwaYW5pryc1Xkl561aRlKZOXFKsgzVHzMnk0okFUonPObZqRyjPWrMUwHesdZcd6lE5HStNjkkm2bX2kAckVFJeADrWU0rMMYoEUj+tAKkt2W5Lw9iaj813PU0R2jHrV6C06ZBoL5owIIYmY5Oa0ILYnHFW4LTgda0re1xjAoMauISRRhtDnpVkWnGcVqR2+3tUxj+XpSep51Su5HO3FtgZIrn7+L5xx3rs7xDtrmdRT5x/vVDMW77nikv8ArX+pqM1JJ/rH+pqOu480ZSVIelNoAY3SmVIeppo6mgBtFObrSYoASnLSjpS0AKtSLUVSKcVNgJ0PrUoPIqsrc1KrUAT5xjmpVYE1XDc1LH1pASjqa9X+HGqq+kiKR/mhO3FeUrW/4RvRa6osbn93J1+tY14c0TtwVTkqWezPd9Onml+ZQFQ8AnvW1ECU+c81zmkS5tgysMAg4rXjvAxGQST7V5p9E1roasYX5cfSrK8Dg4rIW6lI/doTzT0nuWPEZx9aBqLZrZPTPWlzkVRV58fc/Onq8m3lBmgdmWsktgHmql7FujcHrT43dW3FeakmG9ADwx5OKcSZI8P+JmhmffeAYmQcnsVryqRSDjIwK+lvE2ni4glQjIZSCPavnfVrNrK/ntnGCjfp2rsw0vsnj5lSWlRGPIOtVJBzV+QYzVSQda6jySo9MqV+KiNAgoNFJQAUUUUAA6123ww11tK1tbeWQi2n4IzwG7VxIp4JBBXqP0pSjzKxtQqOlPmR9maPcpNEuGByB+BrUhyGO44rxH4TeM0uLdNOvnxcwgAHP+sX/GvabGdZ1wSNw6e9cEoOLPo6VbnjzIvxuBwenrU+4bRzVMsVHXipEcHHWoN1aRdhccHdyOlKzjZt/izmq6nPQ4qVSehOc1VyHHUrXWTnPTpVGRVjXJAIFa0m0qd3QVjXRIQqOc9KiSKiRZEs684A61Q1WHJPl/KD1/8Ar1aiPlRpuB3FupPFRXu+XzEyiEck+v0oRpbY5HUpPILpESNwwcd6b4YuyVuLeQbXRt4+hqfVgsYZdu5jzn1rM0BXGslSMbozu/A1PUmaS1O902XcMZ/Or1y21AdrGsnT2CzD1rWlf93z9a1RhLRnP6qrTA8bQAfrXJ67En2I4444rrdTkwC+epri/ENyGRYl5YsPyzUbMh9zPhtf9GjOD0FRS2prq0s8xJhewqGWxrrURPG9LnF3FuQeAapSRNmuwuLDn7tU30/J+7VWNY4m61OcW2Zu1SLZt6V0MVhj+Graafkfdp3E66OajsmParMdgTj5TXRx2GP4asx2PPQUrmTxFjnI7H/Zq3FY+xreW0H92pltgOtK5jLE36mPDY4PSrsVnjFaCwqBUqqB0ouYSrt7EEUGAKsIuKM0ZouYSm2TLTmHFQK2DSvJ8vvTWpncrXnQ1zl+mZB9a3bqTcDWPcLmQH3pNWC54HIf3jfU03Iol/1r/U02uw4h1ITxRmkoAQ0hpTSGgBKKKKAClFJS0AFLmkopAPU4NTIc1AvXFTIMEUgLCL+dSp1qOPmp4xzSGPSrERaN1ZPvL0NRKKmXrzSeo1o7nrfgvV2exRmG+M4Bb0Nd3Z3cLkY5B6cda8c+H92I3a3bG0nIzXrWnKpX6dK8ypHlkfTUKntKakb0ZUgYGKsqB2xVKF/lUDkVZ8wYyRtxUF6ssK3rikb0P6VCkjPgKpI9QKsCM5B4J9+1ItIIkAXcetTkZQEAcZyaQKfUEfSnk/L2/pVRRUjE1aLeuDhS3BPpXhPxS0z7PfxXSptEnyt7mvoC+ib5RwQOc9a83+J+nC50SUqu54sOP61pTlyzuc2Jpe0pNHg0i9apygVpSrxnHXmqEq9a9G58yUZB6VC1WZRwaqsKBBRRSZoAWiiigAFOWm0qmgC1azy200csDskiHcrDgivcvhr8RI70R2GqsI7tejfwyfj614QvXp1rd0PR5ruVXG5QGyD3qKkE1qdeDqzjK0dj61huxKmN4Poanhmx1IbmvH/D2oahpsCRyStPGBjD8kfjXV6f4mjafy5OGxnpXA1Y+ip3PQ4XBzhQPxqdWz1JB9qw9N1Fbhdyj5fetdZMpwQT7Ui2rjpWiUHI5+tU5MKCxC9OBUr5I+YL+NVpolIwd2fbpRcWxSk2lChIz1FVrucvEWOAyjAwKmnt8bmBK+may+Y2yehP8RzSbsaIoXcZZWaQYGOKydNPla1FngOrDn1xW1qUwHChmY1iwB11O0d+nmEY+oqVuZ1HdHV2wAZSTjJrTfaAN2SKyYjh89K0HYlRzxitLmDMPWtiq23JyeBXD6mWlu7eMkKDIB9a7bVAsZyTwK4m9bzdShPYPxinDWaIqaQZ28RAAHoMVJ5at2rLinPrV2KfI4Neg42PEU7iT2wPYVSa0GTxWqsgbANMcA88VDVjaFRmfHaqOtTrAB2zU20UH2qbFubGiNQOlLtUdqQtimtIKmxHMx+KTIqIy471GZQO9CQrlnIozVbzR601phjrT5SW0iyX96jeTnrVR5j2NRmUk01ATkXfO5xmgyZ6VUUkmpk5q0rGTkNl561UePc4OO9aPlFutNEOGHHepm0VFM+aZf8AWv8AU02nS/61/qabXScqCkzRSUAxaSiigLhSUtGKBiUo5pKUcUAFB5opcUmA5R0qZOaiWpkHNIZYiHNWU4NQRCp14PtSAnTFSHFQjA71IGyKQ0XtGuzZ30UoOMHDe4r2rQtQLwR+WNynnk14LzkV6D4H1kmHyJGyyHHNcuIp395Hr5dVv+6fyPXbeR26LjPfNX4od2N5LVzmmXYI54+lbkMw28H9a4z1uW2xqw4VflGKcGAOM81UjuAer8U/zoyOpJH60XQJO5bGWJHT6d6lRRwGFZyXPIzxir0EokwR604tBJMluYkO0+1cZ4stRNbTJjhlIrt51IjO7qa5rWhmB8jpVSVtTOHVHyzeReXNKnOVYj9azZl4NdJ4kjVNZvFAxiQ1gTL1zXpQ+FHzNWNptGXKOtV3FXJ1IzVSQHFUZER4po61IwqOgBc0oOabSg4oAdQOopuamtU82dF9TS6XBa6I6HwxozX0odx8gNeladYR2yBY1wRVXwxYpBZLhcEgV0UUYHUVx1J8zPpcLh1SjfqRKhx71PalbeZJGA2j5ckZ4p7RilWJSB9c1kdi0O70qKJ4lZfTPHFbkb7E4BNYWiMv2cD2FbSA44osSndlkNuXIOfbFPC8cnHsKjTcRhgAKlLDbhQc0WG0Ub2EMTuZse1Yc1sN/BJHvXSPHvTGMnqayrsZfCjFJq5MZWdjIlhGwkKMjvWNe7Y721br+9HQ1vTgockgnpiuZ10snknjhwf1qEiZO7sdAHGcVcdgYweQPrWM82G461ajctBktVpCcShq0ifMAPxNcnEpm1eJewJNdBqLA7j1rN0OMS6nLJ2RMfjV017xhiNKbRfYFTxTklI71PMmO1U5FIr0FK54bg1sXY7nA5qQXQrFkcqepphnI70NXEpNbm99pHrUb3I9axPtB9aQzE96jlNFM1XuueDURuQe9ZhkY96AxNJRB1DQM+e9RmfPeqgJPrTwuarlRLm3sWRMetIZCeuaYqGpFiOaNCNWNBOeKkQEsOKekJz0qzDDg0rlKLaCGPOKuRRU+GIcVaRAKnmHyEQiAqNlAYcVbbiq8jDdWb1NYxPliU/vX+ppuaWT/WP9TTa7Dzxc0lFFABRRRQAUUUtACYoGTTsU4CgoaBzS4p2KULzSYCL1qeKo1XmpkGCKQFhKmHSoUqVaBjs4608YFQnrT1OaQyX6Ve0e4NrexvkgE4NUR0qReamaurF05uElI9b0rUflXJPPvXT21/0rzXw5Kb3TQUOJ4flI9a6XSLtpcAg56HNeTUjZn19KUa0OY7WO63Y255q9CsjjgE+3rWdpcQIVm/Kus01QwCcKvQ460QpuRE58nQzTG4X5lAP1q3ZMQQD1z6V0cdhB5e0IOO5qlc2qIp8sexrR0nExVdT0HtiSDnriuX1rAicHrW3BNsLIw+YfrWP4gUCFiOpFKUroIrlep80eJwW129J/56GsOVeDW/4gw+sXhH/PQ1jyLXpQ+FHzlf42ZM68Gqci8VqzrwaoTLxVmBRYVGwxU8gIqE9aYhtFBoFIArQ0MA6hEG6bqz6sWDmO6jbPAYUpbFU3aafme76SALVMegrUXmsfwy3nafEc1tqtee9z6uMlZAwBAqNuFP0p7HaMVRurgpuHHSgd2dxoE262TcOcCuliVig6VxHhecPZRE43Z6121vcDaAc5FShbbFmPODjsKeFOeTgVXDgk4BzUgkYHB/IUytWiVjtQgfnWZdQsWLZ4q+XH3SDzUE7YBBAxQZ7Mwb7Eanp7cVyuuqWiznpzXXX4DIS3QVyGuPmHHTJx+tAmXVk3IrNjO0dKsI2IuDVVl2qo9BinxE8+lBp0M/Um2KzNUfhYYhuJGH32x+FR61IPLbJ6Cn6TKsVkqAgHrV09zkxGqsbD4Yc1WmQHpSiYNS7h610XaPPlTKM0XB4qnJC2eK2W2nqBUJiUmq5zOVMxjGwPIpQjelaphXPajyVp8wvZ2M1YmNSpASe9XliXNSrGtDkHKVEt/aplg9qtqox0p4AB6UucOUrJBjtU6w1IMZ6U8EUm7hyjViA61Kqgdqbupd3fNQ2Uok6cdKkDAdaq+cqjk1HNdKB1FBcady3LMBWZc3QDDp1qpe6hgNgisC81Ebxz3pHTToHiEv8ArX+pptLIcSP9TTc12ngjqKSlHSgaFFFApy0AxtOAyKdigUDQlOWinUAFFLQaAHCpUqIVKlJgTL1qQVGvXpUijrSAKctFOWgaHpUqnAqEcGnhs8ZpFI2/Deo/YNSRmP7t/lavSLSOOO6iMR+SQcV4/wBv6+ld54W1sTWMdvN/roT8p9RXJiKd9T18txPI+RnrumLlAa6GxO1h9a5nRZPMt0I5GK6G2chgPSsY6HrS10Omtn8xRReREocdetVbSUcc4rXBWa3JIAwOtb/Ejzp/u5XOXv8AYpBHU8g965/xbcrb6dNK5wFjJ/StvUCst0UzgA8GvMvi1rSwac9pG2Xl+Xj2rkSvKx0ufLHm7Hj11J5s0kpOTIxaqUi8Gp2Pvmo3GRXppWSR83N3dyjMvFZ868VqTDis+ccVRBnS1XerUvSqrUxDDSUppKBMKVG2sD6c0lGaATs0z2PwDqaS2KoW5AFdk0ncdK+f9C1eXTZwysduelek6b4shuIVDtg+5riq05KV0e/hcXGpGzOrurtUXmuQ1nWNpZUbk8CqWteIFcMkbfjmuXnuWmcncSTSjSlLcqvi4046HtHw71D7ZpCNkF0JVs16FbzMVBUkdMZrwD4e60dL1MRTMfImIBz2Ne86c4kUFSSpGR9KzqR5GaYauqkbs0xMRkEnPXipI7mNursso6e9VTwOeKou2GNc8ptbHoRipLQ1prsKCzFuRhfrVbzmYbj8xrPad2K7eQDkirfmEJ604Sb3InGxWv32Ixc5bsPQVxGszEzxIOT5ij9a6/VpCI2LBVwPyrjf+PjWbNlUgKxZsn071sYG/J2HcU0Dg0yaQAfeNQNNticg9RQDlZHPeJ7tI4iAcZrLs9WzgBuBXN+MdXNzqZhjbCRn5vc1n2l4y45reEbK5gpRk7HpdtqX+1V6K/Vv4q88ttQPrWlBqPH3qfMaewud0t0pFSC4BFcfDqRx1qwNS45JquYiWFZ1BnHemmda5sakD3oOoj+9+tBjLDtHSLOtP+0LXL/2hz96nrqHvQT7E6gXK077SK5j+0f9ql/tH/aoD2J032mlFyB1OK5c6kvZuaYdSOeppMaoXOpN4B0aoJL7H8Vc4b3d3NNe6wOtQ5FRoG9JqHB5rPudQ461lNOzdKicsw61EqyR1U6Meot9qDc89qwbm8ZpV+oq3eK9ZUykSL9RUe05jtVONjiZf9Y/1NMpZc+a/wBTSCvVPhx9FFLQAoFPUGm1IBkUDQvUUmDSjinYoGIFpcUUtAXEoFLRQA9alSol61PGO9JgSoKkxTV9qfSAbTgKaTilU9qBjhz0pQMGkXinZoAlBGBU1rO9vMssTEMv61VXJNWEwPqaTV0VGbi00e2eA9Yju9PTccOOCPeu5gulwCCK+efCmqtp14FZsRSdSexr1KHVt6jy5EIx/erzaidN67H0mGrKtBO+p6HDfEDirlnqRcmNX5PGK8/s9QOdzSH8DxVbV/FVtpsLeZKqHsAfmNQpyeyKqxXVnTeIdVttNtp5JZVB55J4xXz74l1d9Y1OS4bIj+6g9qm8S+Ip9cuMtlLcH5Uz196wic12UaVvee54+KxXP7kdhrHmmOc/SngZzTG5HFdBwsrTdOKoT1pSj5aoTrTJM2XoaqsKuzAVVkGKZLK7Ckp7daaaBCUUUUAKKkidk+6SPxqIDNPSiw02ti5G7scsxP41ftxnFULda1LZeBSaG23uW4VwBXqvw88TStGLS8BPljHmf0rzCJeBxXpnw3sVNn5zoCXbvWGIty3Z6GXuXtfI9RgmE6IQcgjrTzZJNndyuenc1Ut7fYq7WZR6dq1oVCL855rgtqe9d20IBaKOCowemKa6Ii9eas7xtKn65qhcyFc7VGB3NO6WxLb6mVrEgKk5AHvXIW7CXWllBwqqwA9eK6LVEaYkTuAo52iufjaM6kSBhY4+n1pp3M7aF25cc81ynizWDZafIsbfO3APpWxqN0UVsYArzXxrOzFFLHk5xWsFzSsY4ipyxOdEjSyF3JLMckmrlvnis6HIOKvwNiuqStocmFnd3L8ZI6GrcbkHg1UiIxVlAaxPcpFpZ2HQ8U8XbDp1qsoyKY4oOjlLJu2zyaBeEHqaokc96Qr9aa2MpJGiL0570/7W3qazEB/CrCrkCg52kXftT/3qPtTep/Oqm0+tKiEjvUNiVi35565NTRyM2ME1BDCSBwa0IICOorGdToKTRLFk45qdYyxp0cYFW4UGa522yYkcdvwBipHtzs4Aq9FGKkdVVMmsJSaKuc5eRYzkVg3QxIuf71dHqkgG7FcvdPumXH96tqTbOundrU4aT/WP9TSDmlk/1r/U0g4r3z4YfSqc0lKooAcOtSLTF609SKAHUo4puaAeaB3HUGjNFAhwp4FR5qRaCh6jFSrTFp+cUmA4U4Goic0q0gJB1pw4pq04d6AAmnAZFKB3ooGPU1Ihx1qFaeDQBaVsCrEOoXcIxFcSJ9DVFDUo5qHFPcuNSUPhZZbU75hg3c2PZqhLs77nZmb1Y5JpMCm9DTUUtkEqkpbjgcGkNHWm9KZL1F6U1ulKelNJ/OgRDL0qnOOKuyDIqpMuRTBmdMtVpRV+YYqpIKCWU3FR96suKhYUCGUmKdg0YoAFFSximKKs26butA7Fi2TJFatumAKq26CtCFeKTGWYRkAV7B4KiFvpkK55IzXkdou+eJPVhXs3hxN0C/QVxYqWyPZyyne8zs9PG9Acj05q1IoU/eI9qoWqFVUgH8KtsSU4Az71zrY9PqNky2TuIFZ94dqEkHP8XtVicnkA1mXrDy2yxz3560mVy3MXVLlQXC4IxXLWTs7XUoOcnbWprU6JFI3QYIrMsx5enpnALEsaERPTQqXz4jzIfl7ivNPEd4LvUHKH92vArqfFuo+WjQxv8x44rh3HPrXdQhb3jx8dWu+RDI+tXrfnFUl61ctPvCtZBhdGadqpNaCLjtVe0Aq5jg1zvQ92lIYV54oZKkiGTUzLUXOrmKfl5pNgzzVsKKhcfNVXOectRVhyOKQRsCRipUbaOTTlIZjzQ2ZahHGO9WIoV45qEsB0NTwtnuK56kmiWW4Y1zwKuovA4qtbFe5q6rKB1rkciHqx4AApocK3WopphiqLz4J5q4PQ6KcLo3Y7kAYzUdxd4XrWILsL3qGe9yMAms5QuaeyuGpTFs+9YLtmde/Iqxczlu9VV/1q/UV0048u51RhZanISf61/qaaDmnS/wCtf6mm17Vj8/HZp4NMFOzQA4UuaZRmgCQGpFqJakoAdS0g6U6gBQOaeOtNWnUDuPBpSfSoxThQMcpqRemajXrUig0mA9SaenXmmigHFICYn06UlN3dqcOaBgKkUGhFqULxmgBoGDUgbHSoy1NLc0AT7qCaiVqN2e/FAEm6kJzTcilHHagBR3puMnNPXntS0AQuDUMi8VabpUUn3TQBnTLVSRea0JhVSVaBFJxzULA1cZfaonQelAmiqQRRg5qYpk0qx0CGxoTV23j9KjiT2q7AtBRNCuOtW0OBUKcdaeWoGaej/NqMA/2q9m8PDEYA6V4lpMuy+hbOAGGa9n8PS7gpDZBrgxS1Pcyt/u2js7U5QAGpmDbc44FVbVhxxVstuBBrnS0O9mbdnArB1CYD7zYrY1aVYI2JrhdUnmm3OAQg6E8ZoZrFqxm6xObqYQRfd3ZY56VS1rUUtodgIG0bRVWWRLQyTyMN7cCuV1K7a7kJJ+XNbUabkefisRGEfMpahO1zMZGOSapFasyVA1eglZWPAnJzd2RYxVm0+8KgqSE7WFRJHZhpWZuW74H4VoRtnrWPBLwKvxy8VzyPeoSujRUKBxTXbFVkmpJJuOtQbu4SSheaptcgt1plzN15qgW5zTElc1/PBHBoEu05zWWkzCn+d60BymibnPepIrkAdayPM+tHmmocbhyo6OK89P51bjvPU1y8U4WrQusDisHSswUNTclu1wcms+a654qkbgnrzTAxbk0KFjqp07EzXDHjJpnmH3puKdiqsjqjBDSCetOjA8xfqKKWP/WL9RQinE42T/WP9TTadIf3j/U02vZPzUKAaSgUAOzTlOaZT1pAPFPpmfSlBOKYDwakXpUK9akU0gJB1px6VGDmloAcvWpKjBFOFA7ki9alSoQeKeppDJloamhqcvI5o2AQVNGOaaq1IvHB6Uhky8ClLVEHphegB55NMPWmiSlzmgQv8VOVqZSDOaBkwOTTulMU4pSaBD1brTs5qIE04NQMdUcnQ07dTWagCtLVaToatSVXkGaBFZhk1GUyaslabsoAr+XShOan24oxQKw2NeatRVEi1MtAyWjOKQHmhutAD4n2yKwOMHNeseBtRWeEITlhXkYzkYre8M6s2nXsbZ+XOCK568OaNz0MurKnLlZ9BWUoKLmrMswVSRXPaLqCXFujq2cjPB6Vdv5gYjtJ54+tcF7aHtyTvYg1BGutzkFkHQZ+8f8A61ctrPyQs0jfMF4rrbmaMWaxJjaOp75rz/xffqiOoIGOtXFXIcrK7OC1m4LzY3ZySay2NS3EhklZj0zmoD1r0aceVHz1ep7SbGtUL9ambpUTA1RiRmhTinEcUlJo2oy5WWIHxV2Kas1DU0bYrmkj3cLO6saQmwKjkuOKrbiaYzc1md7YSSbiaj3UMcmm0ybjwc0oPFNXpS0BcWiilpFocualTPemLUyj0qWbU0PQZqYLxSL0p45rN7nZGIgp46U3BpwNI1sFCf61PrTM0qN+9T6igmTschKv71/qajPFWpl/ev8AU1EY89xXsH5oQUopzLTcYNMBacCMU2ikBIDS5qPNKDxTAkBqRSKhB4pwOKAJ14paiBzT15NIB9SLUdKDmgCUU4HiowacvNA7kik1Og9agXrUobFJjRKDignioi/NJvpJDJC2KYWP4Ude9JTsIXPNP3VHS5osBIDmlHWmrTqQDlPNOJ44poHFJnnrQA4kik3c03OaO3WgB5bmms1N5oxQAEZ60zZzUmKKAIWTmmFamaozzQBGQKAtPC04DFADFXFSAUUtAACMUUEYooABTlcqcjrTaD1oA7Hwt4ia2wjnpxgmu6g162lCmRiAOeK8VBxViO8uEXCyHFck8Ld3R6dHMHGNpanp+reJEiSTb90/dyetefavqUl3Kfmyp61nz3EswxI5IHSoscdeauFBR1ZlXxjqe7FWQN0ptOPSm10HENqNu9PJwaYe9ADCeKYacxqMtQVFXY5c1MpqsrVKprCZ6+FZZU8UGmIc041getF3Qw0lOIzSbeaAHAcUtA6UUikhcUo5opyDpQzSKHxjnmp0qNBUyis2zppolSn4xTF4pxaoZ1oU8U3NBORSYoC4maF/1i/UUlPjH7xfqKZm0zl5T+9f6mm5pjiTzH+Rup7Uqq5/gb8q9c/NxStRlamCOQfkb8qTy3/uN+VAFcjFJU7Quf4G/KozE4/gb8qAGUopRG/9xvypRG/9xvypgIDTs0eW/wDcb8qVUc/wN+VADlNSKaYsb/3G/KpFRhzsb8qQC5pc0m1z/A35UCN8/cb8qAHA1MnSo1jcfwN+VPCuP4W/KgCQNigtxTNr/wB1vyoVHP8AC35UALvpQ3NJ5b/3W/KlCP8A3W/Kgdx4anA1GEf+635U4K/91vyoC4/NKKaEfsjflT1RyPuN+VAxVOKdmk2P/cb8qUq2Put+VKwC7uKjZqXa/wDdb8qaUcn7jflSAN2aetR+W4I+VvyqRVYdEb8qbAfmk780u1v7jflSFX/ut+VIAzSZFKFc/wALflQY3x9xvyoAjJzSAc1II3/uN+VL5bf3G/KgBoX0pGFSqjZ+435U10cn7jflQBDS5pxjf+635Unlv/cb8qAEJzzQDS7H/uN+VAR/7rflQAuKQ04o/wDcb8qaUf8AuN+VABTl6daQI/8Acb8qcsbn+BvypAJR9ak8tv7rflTTG5/gb8qAGZpKd5b/ANxvypjI4/gb8qYxrVGTxUhR/wC435VGyP8A3G/KgCJzUZqVo3P8DflUex/7jflSZtSV2IvepFNMWN/7jflUyxv/AHG/KueR61CNh6nAp4ORTRG+PuN+VOWN/wC435Vm0ehAKKd5b/3G/Kl8t/7rflSNBopcUojb+635U4I/9xvypFITFPQUeW/91vyqVYm/ut+VJm8UKgqZRTFjb+635VKqP/db8qzZ0w0FFLS7G/ut+VKI2P8AC35VJtcbRipPKb+635Uvlv8A3W/KgrQjxTo/9YvHcUuxv7rflT41bzF+Vuo7UA7H/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical herpetiform distribution of cutaneous lesions, including blisters, erosions, crusts, and atrophic scars, in EBS Dowling-Meara.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Epidermolysis bullosa simplex (EBS) of Dowling-Meara",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical herpetiform distribution of cutaneous lesions, including&nbsp;blisters, erosions, crusts, and atrophic scars, in EBS Dowling Meara.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_29_15832=[""].join("\n");
var outline_f15_29_15832=null;
var title_f15_29_15833="Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal";
var content_f15_29_15833=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/29/15833/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/29/15833/contributors\">",
"     Barry Fuchs, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/29/15833/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/29/15833/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/29/15833/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/29/15833/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/29/15833/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distress generally presents as agitation. It is common among critically ill patients, especially those who are intubated or having difficulty communicating with their caregivers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/1\">",
"     1",
"    </a>",
"    ]. Distress needs to be treated for patient comfort and because it increases sympathetic tone, which may have untoward physiological effects [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/2\">",
"     2",
"    </a>",
"    ]. Barring few exceptions (eg, neuromuscular paralysis, procedures) the administration of sedative-analgesic medications should not be based on anticipated distress but rather on that which is observed; otherwise, there will be an increased risk of over sedation and its secondary sequelae.",
"   </p>",
"   <p>",
"    The management of agitation in critically ill patients is reviewed here, including the initiation, maintenance, and withdrawal of pharmacological sedation. Common sedative-analgesic medications, the treatment of pain, and the use of neuromuscular blocking medications in critically ill patients are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25082?source=see_link\">",
"     \"Sedative-analgesic medications in critically ill patients: Properties, dosage regimens, and adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=see_link\">",
"     \"Pain control in the critically ill adult patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43720?source=see_link\">",
"     \"Use of neuromuscular blocking medications in critically ill patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRE-INITIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before a sedative-analgesic agent is initiated to manage agitation, the cause of the distress should be identified and treated. Nonpharmacological strategies should be implemented simultaneously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Identify the cause of distress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common causes of distress in critically ill patients include anxiety, pain, delirium, dyspnea, and neuromuscular paralysis. These etiologies may occur separately or in combination.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anxiety &ndash; Anxiety is defined as a sustained state of apprehension and autonomic arousal in response to real or perceived threats [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/1\">",
"       1",
"      </a>",
"      ]. Fear of suffering, fear of death, loss of control, and frustration due to the inability to effectively communicate are typical causes of anxiety in critically ill patients. Symptoms and signs include headache, nausea, insomnia, anorexia, dyspnea, palpitations, dizziness, dry mouth, chest pain, diaphoresis, hyperventilation, pallor, tachycardia, tremulousness,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypervigilance.",
"      <br/>",
"      <br/>",
"      Identifying and treating the proximate cause of anxiety is always ideal as it may ameliorate both problems. Dyspnea, for example, is a common underlying cause of anxiety among critically-ill patients. Thus, if inadequate ventilator flow is causing dyspnea with resultant anxiety, the ultimate treatment for the anxiety (and underlying dyspnea) may be adjustment of ventilator settings. Alternatively, the abrupt onset of anxiety may prompt further work-up for a cardiopulmonary source.",
"     </li>",
"     <li>",
"      Pain &ndash; Routine patient care (eg, suctioning, repositioning, physical therapy), immobility, trauma, surgery, endotracheal tubes, and other monitoring devices can all produce pain. Evidence of pain may include grimacing, withdrawal, combativeness, diaphoresis, hyperventilation,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tachycardia. While self-report is preferred over behavioral pain scales, pain scales are superior to vital signs alone for assessment of pain [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=see_link&amp;anchor=H3#H3\">",
"       \"Pain control in the critically ill adult patient\", section on 'Assessment and monitoring'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Delirium &ndash; Delirium is an organic mental syndrome. It is defined as an acute and potentially reversible impairment of consciousness and cognitive function that fluctuates in severity [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/1\">",
"       1",
"      </a>",
"      ]. Delirium is common among ICU patients, but it is frequently unrecognized (especially in older individuals) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. Delirious patients have impaired short-term memory, abnormal perception, and intermittent disorientation, which is usually worse at night. Electroencephalography may display diffuse slowing. Delirium due to drug or alcohol withdrawal typically presents as a hyperactive delirium [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link&amp;anchor=H9#H9\">",
"       \"Management of moderate and severe alcohol withdrawal syndromes\", section on 'Delirium tremens (DT)'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link&amp;anchor=H16#H16\">",
"       \"Diagnosis of delirium and confusional states\", section on 'Evaluation'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Delirium is a risk factor for prolonged hospitalization and mortality in critically ill patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/6\">",
"       6",
"      </a>",
"      ]. Risk factors for delirium include electrolyte imbalances (hypocalcemia, hyponatremia), hyperamylasemia, hyperglycemia, azotemia, hepatic disease (hyperbilirubinemia, elevated hepatic enzymes), infections, drug withdrawal, alcohol withdrawal, malnutrition, cancer, cerebrovascular disease, cardiopulmonary disease, advanced age, and some medications (benzodiazepines, corticosteroids, antihistamines, beta blockers, antiarrhythmics, digitalis glycosides,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36889?source=see_link\">",
"       \"Acute toxic-metabolic encephalopathy in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dyspnea &ndash; Dyspnea is a sensation of air hunger or a feeling of suffocation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/1\">",
"       1",
"      </a>",
"      ]. Evidence of dyspnea may include tachypnea, shallow breathing, diaphoresis, tachycardia, use of the accessory muscles of respiration, hypoxemia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypercapnia. Dyspnea may exist despite acceptable blood gas parameters.",
"     </li>",
"     <li>",
"      Neuromuscular paralysis &ndash; All patients undergoing neuromuscular blockade require pharmacological sedation, since neuromuscular paralysis without sedation or adequate pain control is an extremely frightening and unpleasant sensation. Identifying distress in patients undergoing neuromuscular blockade is difficult because the typical physiological responses associated with stress (eg, increased heart rate and blood pressure with stimulation) may not correlate with patient discomfort in this setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43720?source=see_link\">",
"       \"Use of neuromuscular blocking medications in critically ill patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Treat the cause of distress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment of agitation should target the presumed cause of the underlying distress. As an example, a patient who is agitated due to hypoxemia should receive supplemental oxygen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nonpharmacological strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacological strategies for managing agitation should begin simultaneously with therapy targeting the cause of distress (since the cause of the distress is rarely quickly reversible). Nonpharmacological strategies include reassurance, frequent communication with the patient, regular family visits, establishment of normal sleep cycles, and cognitive-behavioral therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/8\">",
"     8",
"    </a>",
"    ]. Examples of cognitive-behavioral therapies include music therapy, guided imagery, and relaxation therapy.",
"   </p>",
"   <p>",
"    This strategy of using nonpharmacological interventions to control agitation, rather than immediately initiating pharmacological sedation, is supported by evidence. A trial randomly assigned 140 mechanically ventilated patients to receive either a strategy of no sedation or a continuous sedative infusion with daily interruption [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/9\">",
"     9",
"    </a>",
"    ]. The no sedation strategy consisted of seeking the cause of distress when a patient became agitated and treating that cause. If the patient remained agitated, additional personnel were then assigned to provide continuous verbal comforting and reassurance. Only after these interventions failed were patients treated with a continuous sedative infusion with daily interruption. The trial found that patients managed with a strategy of no sedation had more ventilator-free days and a decreased length of ICU stay, length of hospital stay, and incidence of delirium. Surviving patients were interviewed approximately two years after randomization to determine if the groups differed in terms of post-traumatic stress disorder, quality of life, depression, or recall of the ICU experience [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/10\">",
"     10",
"    </a>",
"    ]. There were no significant differences between the groups. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INITIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sedative-analgesic medication is indicated when treatment of the cause of the distress and nonpharmacological interventions cannot sufficiently control the agitation. The Society of Critical Care Medicine has published guidelines regarding the selection and initiation of sedative-analgesic medications in critically ill patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Available agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sedative-analgesic medications that are commonly used in the intensive care unit (ICU) include benzodiazepines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    ), opioid analgesics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/50/5927?source=see_link\">",
"     remifentanil",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/53/33622?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    , and neuroleptics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef69394 \" href=\"UTD.htm?33/38/34411\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/3,11\">",
"     3,11",
"    </a>",
"    ]. They differ in their amount of anxiolysis, analgesia, amnesia, and hypnosis (",
"    <a class=\"graphic graphic_table graphicRef51282 \" href=\"UTD.htm?22/0/22539\">",
"     table 2",
"    </a>",
"    ). Their mechanisms, properties, dosage regimens, and potential adverse effects are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25082?source=see_link\">",
"     \"Sedative-analgesic medications in critically ill patients: Properties, dosage regimens, and adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Newer agents for ICU sedation include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24741?source=see_link\">",
"     fospropofol",
"    </a>",
"    (a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    prodrug),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/53/33622?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    (centrally-acting alpha-2-agonist), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/47/23286?source=see_link\">",
"     sevoflurane",
"    </a>",
"    (a polyfluorinated methyl-isopropyl volatile anesthetic) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Safety and efficacy data are limited for these agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25082?source=see_link\">",
"     \"Sedative-analgesic medications in critically ill patients: Properties, dosage regimens, and adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Barbiturates (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"     thiopental",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/15/24823?source=see_link\">",
"     methohexital",
"    </a>",
"    ) could be used to manage agitation during critical illness if the patient is not tolerating or responding to other agents. However, they are not ideal because they do not have potent sedative effects and they can cause profound cardiovascular and respiratory depression, as well as diminished cerebral blood flow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Selection of an agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;No sedative-analgesic agent is sufficiently superior to other agents to warrant its use in all clinical situations. The Society of Critical Care Medicine guidelines favor nonbenzodiazepine agents due to evidence of shorter duration of mechanical ventilation, but the optimal agent for short-term or long-term therapy is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/3\">",
"     3",
"    </a>",
"    ]. &nbsp;Selection of an agent must be individualized according to patient characteristics and the clinical situation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/15\">",
"     15",
"    </a>",
"    ]. Important considerations when selecting a sedative-analgesic agent include the etiology of the distress, expected duration of therapy, and potential interactions with other drugs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Etiology of the distress &ndash; The appropriate initial pharmacological agent for managing agitation due to distress depends upon the cause of the distress. For distress due to anxiety, benzodiazepines are optimal. For distress due to dyspnea or pain, opioids are the agents of choice. For distress due to delirium, neuroleptics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      ) are preferred. Combination therapy is appropriate for patients with more than one cause of distress. As an example, a benzodiazepine plus an opioid is appropriate for a patient whose agitation is due to anxiety and pain. For patients who are intubated and mechanically ventilated and not able to clearly communicate the source of agitation, analgesia is provided first [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=see_link&amp;anchor=H6#H6\">",
"       \"Pain control in the critically ill adult patient\", section on 'Intravenous analgesia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pharmacokinetic modifying variables (eg, age, body weight, renal and hepatic function) and the desired depth of sedation should also be considered whenever a sedative-analgesic agent is selected. Abnormal pharmacokinetic modifying variables can magnify differences among the sedative-analgesic agents (eg, onset, peak, duration of sedation), especially during deep sedation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Initial dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial dose of a sedative-analgesic agent should account for the desired level of sedation, as well as factors that may affect drug metabolism (ie, patient age, body weight, renal function, hepatic function, history of alcoholism, history of drug abuse). Higher doses are appropriate for deeper sedation and larger patients, while lower doses are appropriate for lighter sedation, smaller patients, and patients with advanced age, diminished renal function, or decreased hepatic function. Patients with a history of alcohol or opioid abuse may require higher doses of benzodiazepines or opioids, respectively, to achieve a given effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25082?source=see_link\">",
"     \"Sedative-analgesic medications in critically ill patients: Properties, dosage regimens, and adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence indicates that continuous infusion of a sedative-analgesic prolongs the duration of mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/16\">",
"     16",
"    </a>",
"    ]. As a result, current practice favors intermittent infusions or daily interruption of continuous infusions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/3\">",
"     3",
"    </a>",
"    ]. Clinical practice guidelines for the sustained use of sedatives and analgesics in critically ill adults endorse the initial use of intermittent infusion, with the initiation of continuous infusions with daily interruption in patients who require intermittent infusions more often than every two hours [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/3\">",
"     3",
"    </a>",
"    ] .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Sedation goal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal sedation goal is for the patient to be awake and comfortable with minimal to no distress (eg, 0 on the RASS scale) (",
"    <a class=\"graphic graphic_table graphicRef57874 \" href=\"UTD.htm?4/34/4653\">",
"     table 3",
"    </a>",
"    ), although some patients may require a deeper level of sedation for optimal management. The sedation goal should be ascertained at the bedside for each patient; there is no one size that fits all. The notion that all mechanically ventilated patients should receive sedatives targeted to a specific sedation score, such as a RASS score of -2, will lead to the over sedation of many patients and may slow recovery (eg, by eliminating the opportunity for daily physical therapy). In contrast, a proportion of critically-ill, mechanically-ventilated patients require a very deep level of sedation-analgesia to control agitation or pain. A patient-centered approach, derived by the bedside clinician, is best and should be used to determine the appropriate goal for the depth of sedation. This goal should be determined prior to beginning or escalating sedative-analgesic medications, since this is the target to which initial therapy is titrated. As examples, lighter sedation may be desired when serial neurological exams are required, while deeper sedation may be desired during severe hypoxemic respiratory failure.",
"   </p>",
"   <p>",
"    The goal depth of sedation should be frequently reassessed and adjusted as the patient's sedation requirement becomes more apparent. Some patients require no sedation, while others require deep sedation to be mechanically ventilated without discomfort, agitation, or asynchrony.",
"   </p>",
"   <p>",
"    The depth of sedation is typically assessed during the initiation of pharmacological sedation using criteria such as spontaneous movement and response to verbal and tactile stimuli. Scoring systems have been developed to make evaluation of the depth of sedation more rigorous and quantitative, but these systems are more commonly used during the maintenance of sedative-analgesic therapy, as described below. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MAINTENANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the initiation of the sedative-analgesic agent achieves a calm state, attention should be directed toward monitoring and avoiding excess sedation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maintenance of pharmacological sedation requires that patients be reassessed daily to determine whether their agitation and underlying distress are being adequately managed. Scoring systems have been developed to facilitate this evaluation.",
"   </p>",
"   <p>",
"    There are scoring systems (ie, scales) to assess pain, sedation, and delirium. The scale appropriate for the presumed cause of distress should be employed. As an example, if the distress was felt to be due to anxiety and a benzodiazepine was initiated, then assessment using a sedation scale is appropriate. Alternatively, if the distress was felt to be due to pain and an opioid was initiated, then assessment using a pain scale is appropriate.",
"   </p>",
"   <p>",
"    Once the appropriate scoring system has been used to determine whether the agitation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    underlying distress is sufficiently controlled, the sedative-analgesic medication should be titrated or tapered to meet the therapeutic goals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Scoring systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scoring systems use multiple criteria to determine the amount of pain, depth of sedation, or severity of delirium. An important limitation of the scoring systems is that reference standards do not exist [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain scales &ndash; There exist unidimensional scales (ie, verbal rating scale, visual analogue scale, numeric rating scale) and multidimensional scales (ie, McGill Pain Questionnaire, Wisconsin Brief Pain Questionnaire) to assess a patient's level of pain. The unidimensional scales can be quickly and easily applied in the intensive care unit if the patient is communicative. As an example, the numeric rating scale is a zero to ten point scale on which ten represents the worst pain. Patients choose the number that best describes their pain. The multidimensional scales are more complex and take longer to administer; thus, they may not be appropriate for the intensive care unit.",
"     </li>",
"     <li>",
"      Sedation scales &ndash; There are numerous scoring systems to assess the depth of sedation that are valid and reliable in adults who are mechanically ventilated and critically ill [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/18-22\">",
"       18-22",
"      </a>",
"      ]. Current guidelines support the use of the Richmond Agitation-Sedation Scale (RASS) (",
"      <a class=\"graphic graphic_table graphicRef57874 \" href=\"UTD.htm?4/34/4653\">",
"       table 3",
"      </a>",
"      ) and the Riker Sedation-Agitation Scale (SAS) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/3\">",
"       3",
"      </a>",
"      ]. Alternative scoring systems include the Motor Activity Assessment Scale (MAAS), Minnesota Sedation Assessment Tool (MSAT), Ramsay Sedation Scale (",
"      <a class=\"graphic graphic_table graphicRef65842 \" href=\"UTD.htm?9/41/9883\">",
"       table 4",
"      </a>",
"      ), Bizek Agitation Scale, Sheffield Scale and COMFORT Scale [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/23-26\">",
"       23-26",
"      </a>",
"      ]. The COMFORT scale is a valid and reliable system for children [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Delirium scales &ndash; Many scales and diagnostic instruments have been developed to identify and evaluate delirium, but most exclude critically ill patients due to difficulty communicating with them [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/3\">",
"       3",
"      </a>",
"      ]. However, a rapid bedside instrument that can identify delirium in critically ill patients is the Confusion Assessment Method for the ICU (CAM-ICU) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/27\">",
"       27",
"      </a>",
"      ]. It assesses patients for acute mental status changes or fluctuating mental status changes, inattention, disorganized thinking,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an altered level of consciousness. The CAM-ICU can identify new or persistent delirium, but it doesn't quantify the severity of the delirium. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link&amp;anchor=H17#H17\">",
"       \"Diagnosis of delirium and confusional states\", section on 'Recognizing the disorder'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are pharmacologically paralyzed, monitoring is challenging because the scoring systems cannot determine the level of pain, depth of sedation, or presence of delirium. Heart rate and blood pressure have historically been used as indicators of distress in this situation, but these vital signs are neither sensitive nor specific. We believe that there are two reasonable approaches. Pharmacologically paralyzed patients can be given higher than usual doses of both an",
"    <span class=\"nowrap\">",
"     anxiolytic/amnestic",
"    </span>",
"    and an analgesic to ensure deep sedation. Alternatively, bispectral index (BIS), auditory evoked potentials, or other objective monitoring systems can be used (",
"    <a class=\"graphic graphic_table graphicRef81084 \" href=\"UTD.htm?21/31/22014\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/3\">",
"     3",
"    </a>",
"    ]. The latter approach may limit drug accumulation.",
"   </p>",
"   <p>",
"    Bispectral Index (BIS) monitoring uses Fourier transform analysis of electroencephalographic data to estimate the depth of sedation. It is used primarily during operative anesthesia in patients without underlying neurologic disease. BIS monitoring is not used routinely in the ICU because there are conflicting data regarding its benefit and electromyelographic activity from the scalp muscles creates artifact [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/28-34\">",
"     28-34",
"    </a>",
"    ]. We believe BIS monitoring is a reasonable approach to assessing depth of sedation in ICU patients receiving neuromuscular paralysis; however, we agree that BIS monitoring should not replace the clinical assessment of sedation in the routine management of ICU patients until more favorable data are reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Avoid excess sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sedative-analgesic medications should not be overused because excess sedation may unnecessarily prolong the duration of mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/16\">",
"     16",
"    </a>",
"    ]. Two strategies have been shown in randomized trials to reduce duration of mechanical ventilation and complications related to prolonged mechanical ventilation: intermittent infusions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/16,35\">",
"     16,35",
"    </a>",
"    ] and the daily interruption of continuous infusions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Intermittent infusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;An observational study of 242 patients compared the duration of mechanical ventilation among patients who received a continuous sedative-analgesic infusion to those who received either intermittent sedative-analgesic infusions or no sedative-analgesics based on a nursing protocol [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/35\">",
"     35",
"    </a>",
"    ]. The group that received intermittent infusions or no medication had a shorter duration of mechanical ventilation (median of 56 hours) than the group that received a continuous infusion (median of 185 hours).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Daily interruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daily interruption of sedation refers to discontinuing the continuous sedative-analgesic infusion until the patient is awake and following instructions, or until the patient is uncomfortable or agitated, and deemed to require the resumption of sedation. The rationale for the daily interruption of continuous sedative-analgesic infusions is that it facilitates assessment of the patient's underlying neurologic status, as well as the patient's need for ongoing sedation. This practice is supported by the evidence.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial of 128 patients who were receiving mechanical ventilation and a continuous sedative-analgesic infusion, patients were randomly assigned to continue conventional management or to undergo daily spontaneous awakening trials [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/36\">",
"       36",
"      </a>",
"      ]. The spontaneous awakening trials consisted of interruption of the continuous infusion until the patient was awake. The group whose continuous infusion was interrupted daily had a shorter duration of mechanical ventilation (4.9 versus 7.3 days) and length of ICU stay (6.4 versus 9.9 days), as well as fewer neurodiagnostic tests. Limitations of the trial include that it was performed in a single center, ventilator weaning was not standardized, and the spontaneous awakening trials were monitored closely by study personnel, which is not feasible in most ICUs.",
"     </li>",
"     <li>",
"      A similar trial randomly assigned 336 patients to a daily spontaneous breathing trial and either a daily spontaneous awakening trial or conventional sedation management [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/39\">",
"       39",
"      </a>",
"      ]. The daily spontaneous awakening trial group had decreased one-year mortality (but not 28-day mortality), an increased number of ventilator-free days, a decreased length of ICU stay, and a decreased length of hospital stay. The group also had less cognitive impairment at three months (absolute risk reduction of 20 percent), although there was no difference at 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these trials indicate that daily interruption of continuous sedative-analgesic infusions are beneficial, the benefit may be less or absent if a sedation protocol is also being used [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/41\">",
"     41",
"    </a>",
"    ]. This was illustrated by a multicenter trial in which 430 mechanically-ventilated patients were randomly assigned to receive protocolized sedation (PS) alone or protocolized sedation plus daily interruption (PS+DI) of their continuous sedative-analgesic infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/42\">",
"     42",
"    </a>",
"    ]. The median time to successful extubation, the primary outcome, was seven days in both groups. The PS+DI group had higher mean doses of infusions of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    as well as a greater number of boluses of benzodiazepines and opiates, than the PS group. No differences were noted in the rates of unintentional removal of medical devices, ICU delirium, diagnostic neuroimaging, or tracheostomy. Of note, the average daily dose of midazolam was higher in both groups in this study than in the daily interruption trial described above [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/36\">",
"     36",
"    </a>",
"    ]. The seemingly disparate results from the two clinical trials may be reconciled by the notion that protocolized weaning of sedation by the bedside nurse (as in the control group of the PS versus PS+DI study [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/42\">",
"     42",
"    </a>",
"    ]) can effectively achieve the minimal effective sedative dose requirement for patients. This would explain the lack of any further benefit, when the minimal effective dose is interrupted.",
"   </p>",
"   <p>",
"    Concerns related to patient safety have been a significant obstacle to implementation of daily interruption of continuous sedative-analgesic infusions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. These concerns include the possibility of long-term psychological sequelae (eg, posttraumatic stress disorder [PTSD]) and myocardial ischemia. There is little evidence to support these concerns, as demonstrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An observational study performed using patients from the first randomized trial described above plus contemporaneous patients that were not enrolled in that trial found that patients who received daily interruption of their continuous sedative-analgesic infusion did not experience adverse psychological outcomes and were less likely to have symptoms of PTSD than those who received conventional management [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the trial described above that randomly assigned 336 patients to a daily spontaneous breathing trial and either a daily spontaneous awakening trial or conventional sedation management [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/39\">",
"       39",
"      </a>",
"      ], there was no difference in the frequency of PTSD at 3 or 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective cohort study evaluated 74 patients with risk factors for coronary artery disease who were receiving mechanical ventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/46\">",
"       46",
"      </a>",
"      ]. Electrocardiographic monitoring was performed during the continuous sedative-analgesic infusion and during interruption of the continuous infusion. Myocardial ischemia (defined as ST segment elevation or depression &gt;0.1 mV from baseline lasting 10 minutes or longer) was identified in 24 percent of the patients at some time during the study. Myocardial ischemia was not more common during interruption of the continuous infusion, although heart rate, blood pressure, respiratory rate, and catecholamines increased significantly. The study did not address the cumulative effects of multiple days of interrupting the continuous infusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We believe there is sufficient evidence to justify efforts to minimize sedative-analgesic infusions, although the optimal method (eg, protocol-driven intermittent infusions, daily interruption, or a combination) is not known. Additional studies focusing on efficacy, feasibility, and safety are needed to determine the optimal approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     WITHDRAWAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;When pharmacological sedation is no longer necessary, the sequence and rate of discontinuing the sedative-analgesic agents must be determined:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients receiving more than one sedative-analgesic medication (eg, a benzodiazepine and an opioid), the opioid should be tapered last so that the patient does not awake in pain.",
"     </li>",
"     <li>",
"      The rate of the reduction should be individualized. Generally speaking, abrupt discontinuation is acceptable if the sedative-analgesic agent has been administered for a short duration (&le;7 days). In addition, abrupt discontinuation is also appropriate in patients who have received sedation for greater than seven days who are deeply sedated from prolonged accumulation of medication. However, a gradual reduction (~10 to 25 percent per day) is necessary if the sedative-analgesic agent has been administered for &gt;7 days and the patient exhibits evidence of tachyphylaxis, with increasing dosage required over time to achieve the same level of sedation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important for clinicians to realize that there may be a delay (ie, days) between the moment that reduction of the sedative-analgesic agent begins and the patient begins to awaken, particularly following long-term therapy. This is because lipophilic drugs accumulate in tissue stores and must be mobilized for elimination.",
"   </p>",
"   <p>",
"    During the reduction of the sedative-analgesic medication, the patient should be closely observed for withdrawal symptoms. Acute withdrawal symptoms in this setting appear to be common. In an observational study of 28 mechanically ventilated patients who had been in the ICU for greater than one week, nine patients (32 percent) developed acute withdrawal symptoms when their sedative-analgesic medication was reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/47\">",
"     47",
"    </a>",
"    ]. Higher doses of benzodiazepines and opiates conferred a higher risk of withdrawal.",
"   </p>",
"   <p>",
"    Benzodiazepine withdrawal symptoms include agitation, confusion, anxiety, tremors, tachycardia, hypertension, and fever. Seizures may also occur. The administration of intermittent intravenous or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    (0.5 to 1 mg every 6 to 12 hours) may help protect the patient from developing withdrawal symptoms as the continuous benzodiazepine infusion reduced.",
"   </p>",
"   <p>",
"    Opiate withdrawal symptoms include agitation, anxiety, confusion, rhinorrhea, lacrimation, diaphoresis, mydriasis, piloerection, stomach cramps, diarrhea, tremor, nausea, vomiting, chills, tachycardia, hypertension, and fever. Several strategies have been proposed for preventing opioid withdrawal, including de-escalating the dose, converting to a long-acting barbiturate (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ), and adding an alpha-2-agonist (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/53/33622?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/48\">",
"     48",
"    </a>",
"    ]. However, there are no controlled trials of any strategy and there is no consensus as to the best strategy. Data are limited to case reports, including two reports in which dexmedetomidine was initiated at a dose of 0.7",
"    <span class=\"nowrap\">",
"     mcg/kg/hr",
"    </span>",
"    (with or without a loading dose) and successfully facilitated opioid withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15833/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distress is common in critically ill patients, particularly among those who are intubated or have difficulty communicating with their caregivers. However, many patients may be comfortable without requiring a depressed level of consciousness. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Before a sedative-analgesic agent is initiated to treat agitation due to distress, the cause of the distress should be identified and treated. Nonpharmacological strategies should be implemented simultaneously. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pre-initiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacological sedation is indicated when treatment of the cause of the distress and the nonpharmacological interventions cannot sufficiently control the agitation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Initiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The sedative-analgesic agent and its initial dose are selected on the basis of several factors: the etiology of the distress, the expected duration of therapy, potential drug interactions, the desired depth of sedation, and pharmacokinetic modifying variables. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Available agents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Selection of an agent'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Initial dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend NOT using uninterrupted sedative-analgesic infusions to sedate critically ill patients (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Intermittent infusions, continuous infusions directed by a sedation protocol, or daily interruption of continuous infusions are preferable. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Administration'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Avoid excess sedation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients should be frequently reassessed to determine whether their agitation and underlying distress are being adequately managed. The sedative-analgesic medication should then be titrated or tapered accordingly. Scoring systems have been developed to facilitate the evaluation. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once comfort is achieved initially, the goal depth of sedation should be frequently reassessed and adjusted. As the respiratory failure or other critical illness is treated, the sedative requirement should fall. Thus, daily attempts should be made to reduce the level of sedation, although the rate of the reduction must be individualized. For patients receiving more than one sedative-analgesic medication, we taper the opioid last so that the patient does not awake in pain. During the reduction of sedation, the patient should be closely observed for withdrawal symptoms. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Withdrawal'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13249696\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Karen Tietze, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/1\">",
"      Hansen-Flaschen J. Improving patient tolerance of mechanical ventilation. Challenges ahead. Crit Care Clin 1994; 10:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/2\">",
"      Lewis KS, Whipple JK, Michael KA, Quebbeman EJ. Effect of analgesic treatment on the physiological consequences of acute pain. Am J Hosp Pharm 1994; 51:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/3\">",
"      Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med 2013; 41:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/4\">",
"      Milbrandt EB, Deppen S, Harrison PL, et al. Costs associated with delirium in mechanically ventilated patients. Crit Care Med 2004; 32:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/5\">",
"      McNicoll L, Pisani MA, Zhang Y, et al. Delirium in the intensive care unit: occurrence and clinical course in older patients. J Am Geriatr Soc 2003; 51:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/6\">",
"      Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA 2004; 291:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/7\">",
"      Aldemir, M, Ozen, S, Kara, IH, et al. Predisposing factors for delirium in the surgical intensive care unit. Crit Care 2001; 5:265-70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/8\">",
"      Fontaine DK. Nonpharmacologic management of patient distress during mechanical ventilation. Crit Care Clin 1994; 10:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/9\">",
"      Str&oslash;m T, Martinussen T, Toft P. A protocol of no sedation for critically ill patients receiving mechanical ventilation: a randomised trial. Lancet 2010; 375:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/10\">",
"      Str&oslash;m T, Stylsvig M, Toft P. Long-term psychological effects of a no-sedation protocol in critically ill patients. Crit Care 2011; 15:R293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/11\">",
"      Wunsch H, Kahn JM, Kramer AA, Rubenfeld GD. Use of intravenous infusion sedation among mechanically ventilated patients in the United States. Crit Care Med 2009; 37:3031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/12\">",
"      Candiotti KA, Gan TJ, Young C, et al. A randomized, open-label study of the safety and tolerability of fospropofol for patients requiring intubation and mechanical ventilation in the intensive care unit. Anesth Analg 2011; 113:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/13\">",
"      Mesnil M, Capdevila X, Bringuier S, et al. Long-term sedation in intensive care unit: a randomized comparison between inhaled sevoflurane and intravenous propofol or midazolam. Intensive Care Med 2011; 37:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/14\">",
"      Bracco D, Donatelli F. Volatile agents for ICU sedation? Intensive Care Med 2011; 37:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/15\">",
"      Roberts DJ, Haroon B, Hall RI. Sedation for critically ill or injured adults in the intensive care unit: a shifting paradigm. Drugs 2012; 72:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/16\">",
"      Kollef MH, Levy NT, Ahrens TS, et al. The use of continuous i.v. sedation is associated with prolongation of mechanical ventilation. Chest 1998; 114:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/17\">",
"      Wittbrodt ET. The ideal sedation assessment tool: an elusive instrument. Crit Care Med 1999; 27:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/18\">",
"      Devlin JW, Boleski G, Mlynarek M, et al. Motor Activity Assessment Scale: a valid and reliable sedation scale for use with mechanically ventilated patients in an adult surgical intensive care unit. Crit Care Med 1999; 27:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/19\">",
"      Riker RR, Picard JT, Fraser GL. Prospective evaluation of the Sedation-Agitation Scale for adult critically ill patients. Crit Care Med 1999; 27:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/20\">",
"      Weinert C, McFarland L. The state of intubated ICU patients: development of a two-dimensional sedation rating scale for critically ill adults. Chest 2004; 126:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/21\">",
"      Sessler CN, Gosnell MS, Grap MJ, et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med 2002; 166:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/22\">",
"      Ely EW, Truman B, Shintani A, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA 2003; 289:2983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/23\">",
"      Bizek KS. Optimizing sedation in critically ill, mechanically ventilated patients. Crit Care Nurs Clin North Am 1995; 7:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/24\">",
"      Ambuel B, Hamlett KW, Marx CM, Blumer JL. Assessing distress in pediatric intensive care environments: the COMFORT scale. J Pediatr Psychol 1992; 17:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/25\">",
"      Olleveant N, Humphris G, Roe B. A reliability study of the modified new Sheffield Sedation Scale. Nurs Crit Care 1998; 3:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/26\">",
"      Ramsay MA, Savege TM, Simpson BR, Goodwin R. Controlled sedation with alphaxalone-alphadolone. Br Med J 1974; 2:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/27\">",
"      Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med 2001; 29:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/28\">",
"      Simmons LE, Riker RR, Prato BS, Fraser GL. Assessing sedation during intensive care unit mechanical ventilation with the Bispectral Index and the Sedation-Agitation Scale. Crit Care Med 1999; 27:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/29\">",
"      Deogaonkar A, Gupta R, DeGeorgia M, et al. Bispectral Index monitoring correlates with sedation scales in brain-injured patients. Crit Care Med 2004; 32:2403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/30\">",
"      Mondello E, Siliotti R, Noto G, et al. Bispectral Index in ICU: correlation with Ramsay Score on assessment of sedation level. J Clin Monit Comput 2002; 17:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/31\">",
"      Frenzel D, Greim CA, Sommer C, et al. Is the bispectral index appropriate for monitoring the sedation level of mechanically ventilated surgical ICU patients? Intensive Care Med 2002; 28:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/32\">",
"      Ely EW, Truman B, Manzi DJ, et al. Consciousness monitoring in ventilated patients: bispectral EEG monitors arousal not delirium. Intensive Care Med 2004; 30:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/33\">",
"      De Deyne C, Struys M, Decruyenaere J, et al. Use of continuous bispectral EEG monitoring to assess depth of sedation in ICU patients. Intensive Care Med 1998; 24:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/34\">",
"      Vivien B, Di Maria S, Ouattara A, et al. Overestimation of Bispectral Index in sedated intensive care unit patients revealed by administration of muscle relaxant. Anesthesiology 2003; 99:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/35\">",
"      Brook AD, Ahrens TS, Schaiff R, et al. Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Crit Care Med 1999; 27:2609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/36\">",
"      Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000; 342:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/37\">",
"      Carson SS, Kress JP, Rodgers JE, et al. A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients. Crit Care Med 2006; 34:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/38\">",
"      Schweickert WD, Gehlbach BK, Pohlman AS, et al. Daily interruption of sedative infusions and complications of critical illness in mechanically ventilated patients. Crit Care Med 2004; 32:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/39\">",
"      Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet 2008; 371:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/40\">",
"      Jackson JC, Girard TD, Gordon SM, et al. Long-term cognitive and psychological outcomes in the awakening and breathing controlled trial. Am J Respir Crit Care Med 2010; 182:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/41\">",
"      Mehta S, Burry L, Martinez-Motta JC, et al. A randomized trial of daily awakening in critically ill patients managed with a sedation protocol: a pilot trial. Crit Care Med 2008; 36:2092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/42\">",
"      Mehta S, Burry L, Cook D, et al. Daily sedation interruption in mechanically ventilated critically ill patients cared for with a sedation protocol: a randomized controlled trial. JAMA 2012; 308:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/43\">",
"      Devlin JW, Tanios MA, Epstein SK. Intensive care unit sedation: waking up clinicians to the gap between research and practice. Crit Care Med 2006; 34:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/44\">",
"      Mehta S, Burry L, Fischer S, et al. Canadian survey of the use of sedatives, analgesics, and neuromuscular blocking agents in critically ill patients. Crit Care Med 2006; 34:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/45\">",
"      Kress JP, Gehlbach B, Lacy M, et al. The long-term psychological effects of daily sedative interruption on critically ill patients. Am J Respir Crit Care Med 2003; 168:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/46\">",
"      Kress JP, Vinayak AG, Levitt J, et al. Daily sedative interruption in mechanically ventilated patients at risk for coronary artery disease. Crit Care Med 2007; 35:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/47\">",
"      Cammarano WB, Pittet JF, Weitz S, et al. Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Crit Care Med 1998; 26:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/48\">",
"      Honey BL, Benefield RJ, Miller JL, Johnson PN. Alpha2-receptor agonists for treatment and prevention of iatrogenic opioid abstinence syndrome in critically ill patients. Ann Pharmacother 2009; 43:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/49\">",
"      Maccioli GA. Dexmedetomidine to facilitate drug withdrawal. Anesthesiology 2003; 98:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15833/abstract/50\">",
"      Multz AS. Prolonged dexmedetomidine infusion as an adjunct in treating sedation-induced withdrawal. Anesth Analg 2003; 96:1054.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1606 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-221.179.173.170-312020EB49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_29_15833=[""].join("\n");
var outline_f15_29_15833=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRE-INITIATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Identify the cause of distress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Treat the cause of distress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nonpharmacological strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INITIATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Available agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Selection of an agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Initial dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Sedation goal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MAINTENANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Scoring systems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Avoid excess sedation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Intermittent infusions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Daily interruption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      WITHDRAWAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13249696\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1606\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1606|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/38/34411\" title=\"table 1\">",
"      Drugs to sedate critically ill",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/0/22539\" title=\"table 2\">",
"      Effects of sedative drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/34/4653\" title=\"table 3\">",
"      Richmond sedation scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/41/9883\" title=\"table 4\">",
"      Ramsay sedation scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/31/22014\" title=\"table 5\">",
"      Processed EEG brain monitors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36889?source=related_link\">",
"      Acute toxic-metabolic encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=related_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=related_link\">",
"      Pain control in the critically ill adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25082?source=related_link\">",
"      Sedative-analgesic medications in critically ill patients: Properties, dosage regimens, and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43720?source=related_link\">",
"      Use of neuromuscular blocking medications in critically ill patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_29_15834="Erythropoietic protoporphyria";
var content_f15_29_15834=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Erythropoietic protoporphyria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/29/15834/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/29/15834/contributors\">",
"     Sahil Mittal, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/29/15834/contributors\">",
"     Karl E Anderson, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/29/15834/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/29/15834/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/29/15834/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/29/15834/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/29/15834/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/29/15834/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H3912139\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythropoietic protoporphyria (EPP) is an inherited porphyria characterized by painful, non-blistering photosensitivity usually first noted in early childhood and occurring acutely after sunlight exposure but with little residual skin damage. The EPP phenotype can result from altered activity of one of two enzymes in the heme biosynthetic pathway, either a deficiency of ferrochelatase, or a gain-of-function mutation of the erythroid-specific form of delta-aminolevulinic acid synthase (ALAS2).",
"   </p>",
"   <p>",
"    The etiology, pathogenesis, clinical features, and treatment of EPP will be discussed here. A general overview of porphyrias is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=see_link\">",
"     \"Porphyrias: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3912146\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;EPP was not clearly described until 1961 when Magnus and colleagues published a comprehensive description of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/1\">",
"     1",
"    </a>",
"    ]. The disease is characterized by painful non-blistering photosensitivity. Defining clinical and laboratory manifestations include early onset of symptoms and marked elevation of erythrocyte protoporphyrin that is mostly metal-free rather than complexed with zinc (ie, zinc protoporphyrin). The EPP phenotype can result from altered activity of one of two enzymes in the heme biosynthetic pathway (",
"    <a class=\"graphic graphic_figure graphicRef68187 \" href=\"UTD.htm?24/31/25077\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most families, EPP is due to a deficiency of ferrochelatase (FECH), the last enzyme in the heme biosynthetic pathway. Inheritance in these families is best described as autosomal recessive, because loss-of-function alterations in both FECH alleles are required to cause the disease.",
"     </li>",
"     <li>",
"      Less commonly, the EPP phenotype can occur with gain-of-function mutations of the erythroid-specific form of delta-aminolevulinic acid synthase (ALAS2), the initial enzyme of the heme biosynthetic pathway, which is encoded by a gene on the X chromosome. This variant form of the disease is termed X-linked protoporphyria (XLP).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7689197\">",
"    <span class=\"h2\">",
"     Adult onset EPP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, symptoms of EPP (eg, photosensitivity and hepatopathy) begin in adults. In some cases this is due to an acquired myeloproliferative or myelodysplastic disorder, with expansion of a clone of erythroid precursor cells carrying a FECH mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3912153\">",
"    <span class=\"h1\">",
"     PREVALENCE AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since its description in 1961, EPP has been reported worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]. It is now recognized as the most common porphyria in children and the third most common in adults, after porphyria cutanea tarda and acute intermittent porphyria. Prevalence estimates for the general population based on surveys have ranged from 1:75,000 in the Netherlands to 1:200,000 in Wales [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. EPP is very rare in Africa, and is more common in Asian populations than in Caucasian populations (see",
"    <a class=\"local\" href=\"#H3912202\">",
"     'Etiology and pathogenesis'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3912160\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predominant clinical manifestation in EPP is cutaneous photosensitivity that differs distinctly from the chronic, blistering skin manifestations of the other cutaneous porphyrias. Hepatobiliary complications include protoporphyrin-containing gallstones and, in less than 5 percent of cases, severe liver failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=see_link\">",
"     \"Porphyrias: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3912167\">",
"    <span class=\"h2\">",
"     Skin findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, photosensitivity is first experienced in infancy or early childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/1,4,8\">",
"     1,4,8",
"    </a>",
"    ]. Patients report that shortly after exposure to sunlight they develop severe pain, described as burning, stinging, tingling or a pricking sensation that may be accompanied by redness, swelling, or blanching, lasting from minutes to days (",
"    <a class=\"graphic graphic_table graphicRef57800 \" href=\"UTD.htm?15/1/15390\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=see_link\">",
"     \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When these symptoms resolve there is little or no residual scarring. Therefore, physical findings on examination are often absent, or there may be subtle findings such as thickening or lichenification of the skin on the backs of the hands, especially over the knuckles, and face causing a waxy or leathery texture, loss of lunulae of fingernails, petechiae, ecchymoses and minor scarring on the face and vertical grooving of the lips [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. These changes develop due to repeated exposure to light and are generally seen in patients who do not protect themselves from the sun. Bullae, vesicles, and encrusted lesions (eg, scabs), which are frequent in PCT, are uncommon in EPP [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An acute inflammatory reaction may be seen with extravasation of red cells, deposition of PAS-positive material in the peri-vascular spaces and proliferation of the epidermal basal lamina [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/8,13-17\">",
"     8,13-17",
"    </a>",
"    ]. Immunohistochemistry shows deposition of immunoglobulins and complement [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/18\">",
"     18",
"    </a>",
"    ]. These changes are not specific for EPP and, except for absence of subepidermal blisters, may not be distinguishable from changes seen in the other cutaneous porphyrias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3912195\">",
"    <span class=\"h2\">",
"     Hepatobiliary manifestations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7689019\">",
"    <span class=\"h3\">",
"     Gallstones",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of gallstones is increased in EPP patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/1,19\">",
"     1,19",
"    </a>",
"    ]; this disease should be considered as a possible cause of gallstones in children [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/12\">",
"     12",
"    </a>",
"    ]. Development of stones containing protoporphyrin is related to the overproduction of this water-insoluble porphyrin and its excretion exclusively in bile [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7689026\">",
"    <span class=\"h3\">",
"     Liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cholestatic form of liver disease, referred to as protoporphyric hepatopathy, is the most serious complication of EPP, but fortunately occurs in fewer than 5 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/6,21\">",
"     6,21",
"    </a>",
"    ]. Higher prevalence in some series may reflect referral bias or possibly closer monitoring and earlier detection.",
"   </p>",
"   <p>",
"    Patients with uncomplicated EPP have normal liver function tests, and, although data are limited, little or no elevation in liver protoporphyrin concentration. However, there is little information on liver histology and protoporphyrin content in the majority of EPP patients who have no abnormalities in liver function tests. Hepatopathy develops in EPP when excess protoporphyrin, which has been shown to be cholestatic in rat liver [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/22\">",
"     22",
"    </a>",
"    ], damages hepatocytes and cholangiocytes, resulting in less biliary excretion and a progressive buildup of protoporphyrin in the liver and plasma.",
"   </p>",
"   <p>",
"    It is not clear what predisposes some patients, and not others, to develop hepatopathy. In some cases, protoporphyric hepatopathy was precipitated by another cause of liver disease, such as excess alcohol consumption or viral hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Iron deficiency might also contribute by impairing the conversion of protoporphyrin to heme in the bone marrow, resulting in increasing amounts of protoporphyrin presented to the liver. However, this possibility has not been well studied.",
"   </p>",
"   <p>",
"    This feared complication of EPP results from presentation of protoporphyrin to the liver in amounts that are damaging to hepatocytes and cholangiocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/12\">",
"     12",
"    </a>",
"    ]. Hepatopathy develops in association with a severe FECH mutation and also in patients with ALAS2 mutations, but no clear relationship to specific mutations has been found [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In a mouse model with inherited FECH deficiency, the development of hepatopathy is influenced by genetic background, but important modifier genes have not been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As liver damage and impaired biliary excretion progress, protoporphyrin levels in plasma, erythrocytes, and liver increase, causing more severe photosensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/28\">",
"     28",
"    </a>",
"    ]. Erythrocyte survival is reduced by splenic enlargement, which may stimulate erythropoiesis and further increases in marrow protoporphyrin overproduction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Thus, a vicious cycle results from worsening hepatopathy and increased protoporphyrin production and retention.",
"   </p>",
"   <p>",
"    Protoporphyric hepatopathy often presents as an acutely and rapidly progressive form of liver disease with severe right upper quadrant pain, jaundice, nausea, and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/19,31\">",
"     19,31",
"    </a>",
"    ]. The abdominal pain may be mistakenly attributed to gallstones. Such patients may already have underlying chronic liver disease or cirrhosis with splenomegaly and other evidence of portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/29,32\">",
"     29,32",
"    </a>",
"    ]. Severe hepatopathy may lead to the initial diagnosis of EPP in a patient with a long history of previously unexplained photosensitivity.",
"   </p>",
"   <p>",
"    Histologic damage may be mild at early stages of hepatopathy, but protoporphyrin content is increased in the liver at all stages of this complication [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/33\">",
"     33",
"    </a>",
"    ]. The liver appears black on gross examination due to marked deposition of protoporphyrin and bilirubin [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/28\">",
"     28",
"    </a>",
"    ]. Histologically there is usually micronodular cirrhosis with cholestatic features and marked deposition of protoporphyrin seen as dark brown pigment that is birefringent on polarizing microscopy with a &ldquo;Maltese cross&rdquo; appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. By electron microscopy, protoporphyrin appears as crystalline deposits mainly in hepatocytes but also in Kupffer cells and bile canaliculi, accompanied by ultrastructural damage to the endoplasmic reticulum, mitochondria, and cell membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/33,34,37-39\">",
"     33,34,37-39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7689041\">",
"    <span class=\"h4\">",
"     Associated peripheral neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral neuropathy resembling that seen in the acute porphyrias may develop in late stages of protoporphyric hepatopathy, and may progress to respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. To our knowledge, peripheral neuropathy has been reported only once in the absence of liver failure, although the diagnosis of EPP in that case was not convincing [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and diagnosis of acute intermittent porphyria\", section on 'Peripheral neuropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7688953\">",
"    <span class=\"h2\">",
"     Hematologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild hypochromic microcytic anemia is common in EPP and is often accompanied by low or borderline low serum ferritin levels and decreased transferrin saturation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/43\">",
"     43",
"    </a>",
"    ]. These features suggest the presence of iron deficiency without blood loss, and often a poor response to oral iron administration. While these findings are poorly understood, it has been suggested that the excess protoporphyrin in EPP may down-regulate iron absorption or that there is a redistribution of iron stores [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fluorescence in the marrow due to the accumulation of protoporphyrin is maximal in reticulocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/42,47,48\">",
"     42,47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, a deficiency of iron, which is a substrate for ferrochelatase, might contribute to increased photosensitivity by further impairing the conversion of protoporphyrin to heme in the bone marrow, resulting in increasing amounts of protoporphyrin presented to the skin and liver.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7689066\">",
"    <span class=\"h2\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;EPP was described in the past as a disease that causes non-life-threatening photosensitivity well managed by avoiding sunlight. However, this disease has a greater impact on quality of life than do other cutaneous porphyrias and other diseases that cause photosensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/21,49\">",
"     21,49",
"    </a>",
"    ], because pain in EPP is more acute and intense and necessitates alterations in lifestyle and employment. These adverse consequences are accentuated in children and adults who are undiagnosed and as yet have no explanation for their symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7688960\">",
"    <span class=\"h2\">",
"     Long term course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manifestations of EPP are believed to be quite constant from childhood through adult life, with variations in skin manifestations primarily related to the degree of sun exposure. However, there have been few observations of this disease to confirm that porphyrin levels in erythrocytes and plasma are constant over the long term. Such observations are complicated by lack of widespread availability of assays for total erythrocyte protoporphyrin and plasma porphyrins. (See",
"    <a class=\"local\" href=\"#H3912289\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For unclear reasons, pregnancy may be associated with decreased protoporphyrin levels and improvement in photosensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3912202\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3912210\">",
"    <span class=\"h2\">",
"     Molecular pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic EPP phenotype can be due either to a deficiency of ferrochelatase activity (FECH) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/52,53\">",
"     52,53",
"    </a>",
"    ] or, less commonly, from gain-of-function mutations of the erythroid form of delta-aminolevulinate synthase (ALAS2) (",
"    <a class=\"graphic graphic_figure graphicRef68187 \" href=\"UTD.htm?24/31/25077\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=see_link&amp;anchor=H3#H3\">",
"     \"Porphyrias: An overview\", section on 'Enzymes and intermediates'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3912217\">",
"    <span class=\"h3\">",
"     EPP due to FECH deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the majority of families, EPP results from reduction of FECH activity to less than approximately 30 percent of normal, due to loss-of-function variants affecting",
"    <strong>",
"     both",
"    </strong>",
"    FECH alleles.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A severe FECH mutation inherited from one parent and a common low-expression allele (ie,",
"      <span class=\"nowrap\">",
"       IVS3-48T/C)",
"      </span>",
"      from the other parent is the most common finding. The low expression allele is estimated to occur in approximately 10 percent of the Caucasian population, is more common in Japan and China, and very rare in Africans [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/47,48,54,55\">",
"       47,48,54,55",
"      </a>",
"      ]. The low-expression allele by itself does not cause disease even when present in the homozygous state.",
"     </li>",
"     <li>",
"      Because inheritance of both a severe FECH mutation and the low-expression allele is required for development of EPP in such families, inheritance is best described as autosomal recessive, rather than as autosomal dominant with variable penetrance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The FECH gene was sequenced in 1990 and spans 45 kb [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/56\">",
"     56",
"    </a>",
"    ]. It is located on the long arm of chromosome 18 and codes for an enzyme with 423 amino acids [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. The enzyme exists as a homodimer in the inner mitochondrial membrane. While FECH is essential for heme formation, it is not specific for iron and can utilize other metals, including zinc, to form other metalloporphyrins such as zinc protoporphyrin.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many disabling FECH mutations have been described in different EPP families, including missense, nonsense, and spice site mutations and deletions that lead to absent or reduced enzyme activity.",
"     </li>",
"     <li>",
"      Haplotype segregation methods contributed to the initial identification of the",
"      <span class=\"nowrap\">",
"       IVS3-48T/C",
"      </span>",
"      allele in EPP families. This variant results in increased use of an aberrant splice site and an aberrantly spiced mRNA that is more prone to degradation, leading to a decreased amount of FECH enzyme [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rarely, the disease is due to severe mutations affecting both alleles, with at least one allele functioning to produce some functioning FECH enzyme protein [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/30,59-62\">",
"       30,59-62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Under normal conditions, FECH can utilize zinc as an alternative to iron, forming zinc protoporphyrin rather than heme. However, when FECH activity is deficient in EPP, excess protoporphyrin accumulates as metal-free protoporphyrin rather than zinc protoporphyrin.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Accumulation of",
"      <strong>",
"       metal-free",
"      </strong>",
"      <strong>",
"       protoporphyrin",
"      </strong>",
"      (&gt;90 percent of total erythrocyte protoporphyrin), as most conveniently measured in circulating erythrocytes, is a distinctive feature of EPP due to the FECH deficiency.",
"     </li>",
"     <li>",
"      A greater proportion of zinc protoporphyrin (10 to 50 percent of total erythrocyte protoporphyrin) is found in X-linked protoporphyria (in which FECH deficiency is not present) than in EPP due to FECH deficiency.",
"     </li>",
"     <li>",
"      Protoporphyrin that accumulates in other erythrocyte disorders, such as iron deficiency, lead poisoning, and anemia of chronic disease, is predominantly zinc protoporphyrin, since FECH activity is not appreciably decreased in these conditions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3912224\">",
"    <span class=\"h3\">",
"     X-linked protoporphyria",
"    </span>",
"    &nbsp;&mdash;&nbsp;It was known that in some families EPP was not associated with FECH mutations or reduced FECH enzyme activity. Erythrocytes in these variant cases were noted to contain more zinc protoporphyrin than in cases with FECH deficiency, but otherwise the phenotypes were similar. The inheritance patterns in such families suggested sex-linked inheritance, which led to sequencing of the delta-aminolevulinic acid synthase (ALAS2) gene, the only gene on the X chromosome that encodes an enzyme in the heme biosynthetic pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ALAS2 is transcribed only in bone marrow erythroblasts, whereas the ubiquitous (or housekeeping) form of this initial enzyme in the heme biosynthetic pathway (ALAS1) is transcribed in all tissues including the liver. Loss-of-function ALAS2 mutations had been previously described in X-linked sideroblastic anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36441?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes of congenital and acquired sideroblastic anemias\", section on 'X-linked sideroblastic anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    X-linked protoporphyria (XLP) was found to be due to short C-terminal deletions that lead to enzymatic",
"    <strong>",
"     gain",
"    </strong>",
"    -of-function, with overproduction of ALA and subsequent pathway intermediates. Protoporphyrin is produced in these cells in amounts that exceed that needed for heme synthesis, resulting in increased levels of protoporphyrin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3912238\">",
"    <span class=\"h3\">",
"     Other molecular defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;FECH and ALAS2 mutations have not been identified in up to 5 percent of EPP families. Abnormal expression of mitoferrin-1, a mitochondrial transporter of iron, has been found in some EPP patients, an indication that other molecular defects may contribute to this phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3912245\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protoporphyrin concentration in erythrocytes exceeds that in plasma in EPP. However, protoporphyrin contained in circulating erythrocytes, which are no longer active in hemoglobin synthesis, does not account for the amounts of protoporphyrin that are overproduced and excreted in EPP.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone marrow reticulocytes are considered the predominant source of the excess protoporphyrin entering plasma, with an additional, smaller amount provided by circulating erythrocytes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Production of protoporphyrin by the bone marrow may increase further in EPP under conditions in which erythropoiesis is stimulated, leading to further increases in plasma and erythrocyte protoporphyrin levels. The liver had been proposed as an additional source of excess protoporphyrin, but this is now considered unlikely [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Free protoporphyrin in erythrocytes is bound to hemoglobin, and light irradiation may promote its release from hemoglobin and erythrocytes, perhaps thereby increasing plasma porphyrin levels and photosensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/66\">",
"     66",
"    </a>",
"    ]. Metal-free protoporphyrin diffuses from circulating erythrocytes into plasma more readily than does zinc protoporphyrin, most of which remains within erythrocytes for their full life span [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/67\">",
"     67",
"    </a>",
"    ]. As a result, free protoporphyrin content of red blood cells declines with increasing red blood cell age in EPP, and &ldquo;fluorocytes&rdquo; seen on peripheral blood smears by fluorescence microscopy are younger erythrocytes still containing large amounts of free protoporphyrin [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/52,67-69\">",
"     52,67-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The excess free protoporphyrin thus produced in both types of EPP circulates in plasma bound to albumin and is taken up by the liver for secretion into bile [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/66,68,70\">",
"     66,68,70",
"    </a>",
"    ], the only mechanism for removing this water-insoluble dicarboxylate porphyrin from the body (",
"    <a class=\"graphic graphic_table graphicRef75386 \" href=\"UTD.htm?29/55/30588\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Protoporphyrin is hydrophobic and deposited in lipid layers, such as cell membranes, and may distribute differently in tissues than do other porphyrins that are hydrophilic. Porphyrins are photoactive and absorb light and enter an excited energy state, also known as a triplet form [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/71\">",
"     71",
"    </a>",
"    ]. They can then transfer energy to dissolved oxygen to form the superoxide ion (O",
"    <sub>",
"     2",
"    </sub>",
"    <sup>",
"     -",
"    </sup>",
"    ) that in turn can form hydroxyl ions (OH",
"    <sup>",
"     -",
"    </sup>",
"    ). These highly oxidizing species of oxygen can interact with many biological molecules, such as proteins, lipids, and DNA, and form adducts with carbon-carbon double bonds [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. Porphyrin photoreactivity causes tissue damage through lipid peroxidation, oxidation of nucleic acids and polypeptides, complement activation, and mast cell degranulation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/13,73,75-77\">",
"     13,73,75-77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3912289\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;EPP should be considered in patients with photosensitivity and especially painful non-blistering photosensitivity beginning in childhood. A high index of suspicion is needed, and the diagnosis is readily ruled in or out if suspected. It is unfortunate that delay in diagnosis of this disease may be greater than with any other type of porphyria [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of EPP is confirmed by demonstrating both of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased",
"      <strong>",
"       total",
"      </strong>",
"      erythrocyte protoporphyrin (usually 300 to 4000",
"      <span class=\"nowrap\">",
"       mcg/dL;",
"      </span>",
"      normal &lt;80),",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      Increased percentage of free erythrocyte protoporphyrin (&gt;90 percent in FECH deficiency and 50 to 90 percent in those with X-linked protoporphyria).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8738170\">",
"    <span class=\"h2\">",
"     Erythrocyte protoporphyrin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary screening test for EPP is measurement of total erythrocyte protoporphyrin, which normally ranges up to approximately 80",
"    <span class=\"nowrap\">",
"     mcg/dL.",
"    </span>",
"    The most reliable assays extract and measure all erythrocyte porphyrins fluorometrically and express the total as protoporphyrin (porphyrins in erythrocytes are almost entirely protoporphyrin except in congenital erythropoietic porphyria). The upper limit of normal varies with age and among laboratories, but this is not problematic for diagnosis of EPP because values in these patients are markedly elevated to approximately 300 to 4000",
"    <span class=\"nowrap\">",
"     mcg/dL.",
"    </span>",
"    As will be discussed, confusion among laboratories about terminology and methods for measuring erythrocyte porphyrins can complicate testing for EPP.",
"   </p>",
"   <p>",
"    An increase in total erythrocyte protoporphyrin concentration is a nonspecific finding, and can occur in almost any erythrocytic condition, including iron deficiency, lead poisoning, anemia of chronic disease, and hemolytic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. But in all such conditions, the excess is mostly zinc protoporphyrin, whereas in EPP it is predominantly metal-free protoporphyrin. Therefore, when EPP is suspected it is essential to fractionate the total and report the amounts that are zinc protoporphyrin and free protoporphyrin.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In EPP due to FECH deficiency the proportion is almost always more than 90 percent free protoporphyrin and less than 10 percent zinc protoporphyrin.",
"     </li>",
"     <li>",
"      In X-linked protoporphyria, in which FECH activity is normal, there is usually still a predominance of free protoporphyrin, but the proportion of zinc protoporphyrin is 10 to 50 percent. This can almost always differentiate X-linked protoporphyria from EPP due to FECH deficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unfortunately, some laboratories use a fluorescence instrument for measuring erythrocyte protoporphyrin that was originally developed for screening for lead poisoning and is tuned to measure only zinc protoporphyrin, and then reports results incorrectly as &ldquo;erythrocyte protoporphyrin&rdquo; or &ldquo;free erythrocyte protoporphyrin&rdquo;. Therefore, one must select a laboratory that measures total erythrocyte protoporphyrin and can then fractionate metal-free and zinc protoporphyrin. Currently recommended certified laboratories in the United States that can perform this fractionation include ARUP Laboratories, Mayo Medical Laboratories, and the Porphyria Laboratory at the University of Texas Medical Branch at Galveston. Appropriate laboratories at specialist centers in Europe can be accessed through the website of the",
"    <a class=\"external\" href=\"file://www.porphyria-europe.com/index.asp\">",
"     European Porphyria Network",
"    </a>",
"    (Epnet).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8738177\">",
"    <span class=\"h2\">",
"     Plasma porphyrins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total plasma porphyrin concentration is elevated in most EPP patients, but less so than in other cutaneous porphyrias, and may be normal in milder cases. Therefore, plasma porphyrin measurement is not completely reliable for diagnosis of EPP. The fluorescence peak in EPP diluted in buffer at neutral pH is near 634 nm, in contrast to a peak near 626 nm in variegate porphyria and near 620 nm in porphyria cutanea tarda and congenital erythropoietic porphyria (",
"    <a class=\"graphic graphic_table graphicRef60572 \" href=\"UTD.htm?4/23/4477\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/6\">",
"     6",
"    </a>",
"    ]. Protoporphyrin in plasma in EPP is especially sensitive to light exposure. Accordingly, great care should be taken to avoid exposing samples to light during processing.",
"   </p>",
"   <p>",
"    Total porphyrins in feces may be normal or modestly increased in EPP and consist mostly of protoporphyrin (",
"    <a class=\"graphic graphic_table graphicRef75386 \" href=\"UTD.htm?29/55/30588\">",
"     table 2",
"    </a>",
"    ). Urinary porphyrins, delta-aminolevulinic acid, and porphobilinogen are normal. With development of protoporphyric hepatopathy, urinary coproporphyrin increases, as in liver disease from any cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8738184\">",
"    <span class=\"h2\">",
"     DNA studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;DNA studies are more important in EPP than in most other porphyrias as they will both confirm the diagnosis and enable genetic counseling. Whether an offspring of a patient with EPP due to a severe FECH mutation trans to the",
"    <span class=\"nowrap\">",
"     IVS3-48T/C",
"    </span>",
"    hypomorphic allele is at risk for having EPP depends on whether the other parent carries the reduced function",
"    <span class=\"nowrap\">",
"     IVS3-48T/C",
"    </span>",
"    allele, which is common in many populations. (See",
"    <a class=\"local\" href=\"#H3912202\">",
"     'Etiology and pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Genetic counseling is quite different in families with ALAS2 mutations, since the disorder is X-linked (ie, X-linked protoporphyria, XLP). In such families, the disease occurs mostly in males, but may occur in females if the phenomenon of random X chromosome inactivation (lyonization) affects the normal X chromosome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3912296\">",
"    <span class=\"h1\">",
"     TREATMENT AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since there is no effective way of lowering circulating porphyrin levels, it is most important to advise patients to avoid sunlight or fluorescent light as much as possible. This requires considerable adjustments in lifestyle and may limit employment opportunities.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of protective clothing is important when outdoors; as in other cutaneous porphyrias, window glass is not protective when indoors.",
"     </li>",
"     <li>",
"      Acute cutaneous symptoms generally resolve within hours or days, but may benefit from non-specific symptomatic treatment with cold compresses, anti-inflammatory medications and glucocorticoids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3912303\">",
"    <span class=\"h2\">",
"     Beta-carotene for photoprotection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients note increased tolerance to sunlight with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    use, especially in the summer. Beta-carotene was first shown to be effective in increasing sunlight tolerance in EPP in 1970 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/80\">",
"     80",
"    </a>",
"    ]. Since then at least 16 studies (including 12 case series, three uncontrolled trials, one controlled cross over study, and a systematic review) have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/81-97\">",
"     81-97",
"    </a>",
"    ]. In the largest series with 133 patients, 22 reported no effect and 111 reported moderate to substantial improvement in sunlight tolerance, whereas in the crossover study there was no difference between the beta-carotene and placebo-treated arms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral doses of 30 to 300 mg (1 to 10 capsules) daily in adults, and maintaining serum carotene levels in the range of 600 to 800",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      have been recommended. Suggested doses in children are in the range of 30 to 150",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (1 to 5 capsules). Capsules may be opened and the contents mixed into orange or tomato juice to aid administration.",
"     </li>",
"     <li>",
"      A protective effect may develop in one to three months.",
"     </li>",
"     <li>",
"      The proposed protective mechanism is quenching of oxygen free radicals by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      . Plasma and erythrocyte protoporphyrin levels are not affected. (See",
"      <a class=\"local\" href=\"#H3912245\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mild, dose-related skin discoloration, especially on the palms of the hands, is expected because an effective dose is associated with carotenemia. A pharmaceutical grade",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    product was developed specifically for treating EPP. It was originally available by prescription but is now an over-the-counter product (Lumitene&reg; Tishcon). Some patients believe that they benefit by taking beta-carotene mostly in spring and summer, which permits greater sunlight exposure and acquisition of a suntan that provides further sunlight protection. Patients generally have milder symptoms in winters when there is less sun exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3912310\">",
"    <span class=\"h2\">",
"     Other methods of photoprotection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other methods of photoprotection have been employed, with variable success. Vitamin C did not show benefit in a double blind randomized controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral cysteine, which is available as a nutritional supplement, may improve light tolerance in EPP by quenching excited oxygen species at doses of 500 mg twice daily [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/99,100\">",
"       99,100",
"      </a>",
"      ]. N-acetylcysteine, a closely related product was shown to be ineffective in two double blind crossover placebo-controlled trials [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/101,102\">",
"       101,102",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Occlusive sunscreen preparations are of some benefit. Darkening of the skin with topical application of dihydroxyacetone and Lawson (naphthoquinone) has been described, but may have potential adverse cosmetic effects and carcinogenic potential with long term use, and is not recommended [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/103-105\">",
"       103-105",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Narrow wavelength phototherapy that provides exposure to UV-B, which stimulates melanin formation but does not activate porphyrins, has been described as beneficial [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Afamelanotide, a synthetic analogue of alpha-melanocyte stimulating hormone, acts to increase skin pigmentation and has shown efficacy in reducing phototoxicity in EPP in early studies [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/107\">",
"       107",
"      </a>",
"      ]. Larger phase II and III trials are underway in Europe and the United States.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3912317\">",
"    <span class=\"h2\">",
"     Additional management considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron supplements are warranted in patients with low or marginal levels of serum ferritin. Responses, however, have been variable. Iron may be poorly absorbed, and some patients have had unexplained worsening of photosensitivity with iron therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/108-111\">",
"     108-111",
"    </a>",
"    ]. In such cases it is possible that correction of iron deficiency may have transiently increased erythropoiesis, with resulting protoporphyrin accumulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3912324\">",
"    <span class=\"h2\">",
"     Treatment of gallstones and protoporphyric hepatopathy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21714462\">",
"    <span class=\"h3\">",
"     Gallstones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of gallstones is the same as in patients without EPP. Cholecystectomy may be needed during childhood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10374?source=see_link\">",
"     \"Approach to the patient with incidental gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8738288\">",
"    <span class=\"h3\">",
"     Management of hepatopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Especially for patients with decompensated hepatopathy, a combination of treatments is often used, none of which has been validated in controlled trials, given the rarity and severity of the disorder. The aim is to reduce the amount of protoporphyrin delivered to the liver and also ameliorate its toxic effects, allowing the liver a chance to recover [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/112\">",
"     112",
"    </a>",
"    ]. More often this approach helps to bridge patients to liver transplantation.",
"   </p>",
"   <p>",
"    A regimen for patients with severe and rapidly progressing hepatopathy may include some or all of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/113\">",
"     113",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"       hemin",
"      </a>",
"      has been found to reduce plasma porphyrin levels presumably by reducing protoporphyrin production by the marrow, but the mechanism is not established [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/114-117\">",
"       114-117",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Plasmapheresis may reduce the plasma porphyrin concentration up to 40 percent and thereby reduce liver uptake of protoporphyrin from the plasma compartment, which is important because hepatic uptake is from plasma [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/118,119\">",
"       118,119",
"      </a>",
"      ]. Erythrocyte exchange has also been used, because the amount of protoporphyrin in erythrocytes greatly exceeds that in plasma [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/120\">",
"       120",
"      </a>",
"      ]. However, this may be less successful because the aim in the treatment of hepatopathy is to lower the level of plasma protoporphyrin, which derives primarily from the marrow rather than circulating erythrocytes.",
"     </li>",
"     <li>",
"      It is important to correct anemia by erythrocyte transfusions. Even if well tolerated, anemia can stimulate erythropoiesis and increase overproduction of protoporphyrin by the bone marrow. Transfusion to a higher level is a possible approach [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/115,121\">",
"       115,121",
"      </a>",
"      ], but is difficult in patients with shortened red cell survival due to splenomegaly.",
"     </li>",
"     <li>",
"      Ursodeoxycholic acid may increase biliary excretion of protoporphyrin. Chenodeoxycholic acid should be avoided because of potential hepatotoxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/122,123\">",
"       122,123",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"       Cholestyramine",
"      </a>",
"      can be used to interrupt the enterohepatic circulation of protoporphyrin and thereby reduce plasma protoporphyrin levels [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/124,125\">",
"       124,125",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vitamin E can be used to reduce oxidative damage to hepatocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/126\">",
"       126",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3912331\">",
"    <span class=\"h2\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver transplantation for protoporphyric hepatopathy was first reported in 1980; subsequent experience has expanded to more than 40 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/127,128\">",
"     127,128",
"    </a>",
"    ]. Compilation of cases in the United States and European transplant registries has shown that even though liver disease commonly recurs, overall survival is comparable to that of patients transplanted for other liver diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/114,129,130\">",
"     114,129,130",
"    </a>",
"    ]. As an example, in United States patients, adult post-transplant survival was 85 percent at one year and 69 percent at five years. Biliary complications occurred in 45 percent of patients, which is higher than in other liver transplant recipients. This is attributed to high levels of protoporphyrin in bile and damaging effects of &ldquo;toxic bile&rdquo; on cholangiocytes. Therefore, construction of a Roux loop to more safely transport &ldquo;toxic bile&rdquo; has been recommended in preference to duct-to-duct anastomosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/114,129,130\">",
"     114,129,130",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The peri-operative course in these patients is often complicated by severe motor neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/41\">",
"     41",
"    </a>",
"    ]. This may be prevented or lessened in severity with the use of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"     hemin",
"    </a>",
"    and plasmapheresis prior to liver transplantation, although controlled studies are lacking. Dosages of hemin have been similar to those used in acute porphyrias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3398?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of acute intermittent porphyria\", section on 'Treatment of the acute attack'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because these patients have very high plasma porphyrin levels at the time of surgery, there is a risk of phototoxicity to the skin and visceral surfaces from the surgical lighting. Protective filters can prevent this phototoxicity. Three types of filters have been studied: CLS-200-X and TA-81 from Madico Inc. (Woburn, MA), and 61011 from Reflective SA (Cretil, France). CLS-200-X has the least visual distortion, while TA-81 and 61011 offer more protection. These authors recommended 61011 filters as the best compromise between visual distortion and light protection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Liver transplantation restores normal liver function but does not correct the metabolic abnormality in the bone marrow, which continues to produce excessive amounts of protoporphyrin. Patients should be monitored closely to avoid anemia, iron deficiency, and other factors that may cause the bone marrow to produce greater amounts of protoporphyrin. However, recurrent liver disease has been reported as early as eight months after transplantation. There is anecdotal evidence that chronic plasmapheresis and intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"     hemin",
"    </a>",
"    can stabilize and improve recurrent protoporphyric hepatopathy after liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/132\">",
"     132",
"    </a>",
"    ]. Patients with recurrent hepatopathy should be considered for sequential bone marrow transplantation (see below) to avoid loss of the grafted liver [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/114,133\">",
"     114,133",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3912338\">",
"    <span class=\"h2\">",
"     Bone marrow transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow transplantation in mouse models leads to long term cure of EPP and prevents further liver damage [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/134,135\">",
"     134,135",
"    </a>",
"    ]. Marrow transplantation in a patient with EPP was first reported in 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/136\">",
"     136",
"    </a>",
"    ]. While the indication in this case was adult-onset leukemia, the procedure corrected her EPP genotype and phenotype to that of her sibling donor. Subsequently, at least five additional cases have been reported, either after liver transplantation or after reversal of severe cholestasis, with documented resolution of the disease in four and failure of marrow engraftment in the fifth [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/112,130,133\">",
"     112,130,133",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfortunately, it is not possible at present to predict which patients with EPP are at greatest risk to develop cholestatic liver disease and then target such individuals for early bone marrow transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21714418\">",
"    <span class=\"h1\">",
"     EVALUATION AND MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythrocyte and plasma porphyrin levels and liver function tests should be monitored at least yearly. Because EPP patients avoid sunlight, they are very likely to develop vitamin D deficiency. Therefore, a daily intake of 800 international units of vitamin D and 1000 mg of calcium is generally recommended, as in normal individuals, either in the diet or with supplements. Measurements of serum 25-hydroxy vitamin D are recommended to be sure that adequate vitamin D status is maintained.",
"   </p>",
"   <p>",
"    At present, it is not possible to identify those patients at risk of developing EPP-related liver disease. Yearly follow up may be useful to identify early onset of liver dysfunction and to avoid other possible causes of liver disease that may precipitate protoporphyric hepatopathy.",
"   </p>",
"   <p>",
"    Exposure to alcohol and hepatotoxic drugs, drugs or hormone preparations that impair hepatic excretory function, and calorie restriction should be avoided, and hepatitis A and B vaccinations should be provided.",
"   </p>",
"   <p>",
"    Abnormal liver function tests should be evaluated to exclude biliary obstruction due to stones and establish the cause and extent of liver damage. Any reversible precipitating causes should be sought and treated. Liver biopsy may be required to plan further management aimed to prevent progression to liver failure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/29/15834/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3912345\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12440608\">",
"    <span class=\"h2\">",
"     Disease overview",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Erythropoietic protoporphyria (EPP) is characterized by painful non-blistering photosensitivity experienced from early childhood and persisting throughout life. (See",
"      <a class=\"local\" href=\"#H3912167\">",
"       'Skin findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Protoporphyrin-containing gallstones are common. Severe cholestatic hepatopathy develops in &lt;5 percent of cases and may be life threatening. (See",
"      <a class=\"local\" href=\"#H3912195\">",
"       'Hepatobiliary manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The disease is most commonly due to a deficiency of ferrochelatase (FECH), and less commonly due to gain-of-function mutations of the X-linked erythroid-specific form of delta-aminolevulinic acid synthase (X-linked protoporphyria, XLP). (See",
"      <a class=\"local\" href=\"#H3912210\">",
"       'Molecular pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rarely, myeloproliferative or myelodysplastic disorders with expansion of an abnormal clone of erythrocyte precursor cells may lead to late-onset EPP. (See",
"      <a class=\"local\" href=\"#H7689197\">",
"       'Adult onset EPP'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3912352\">",
"    <span class=\"h2\">",
"     Suspecting and confirming the diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EPP should be suspected in any patient with a history of non-blistering painful photosensitivity; significant skin findings may be absent on examination. (See",
"      <a class=\"local\" href=\"#H3912167\">",
"       'Skin findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is confirmed by demonstrating both of the following (see",
"      <a class=\"local\" href=\"#H8738170\">",
"       'Erythrocyte protoporphyrin'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Increased",
"      <strong>",
"       total",
"      </strong>",
"      erythrocyte protoporphyrin (usually 300 to 4000",
"      <span class=\"nowrap\">",
"       mcg/dL;",
"      </span>",
"      normal &lt;80),",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      Increased percentage of free erythrocyte protoporphyrin (&gt;90 percent in FECH deficiency and 50 to 90 percent in those with X-linked protoporphyria)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A DNA study to confirm the presence of either FECH or ALAS2 mutations is essential for well-informed genetic counseling. (See",
"      <a class=\"local\" href=\"#H8738184\">",
"       'DNA studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3912359\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow transplantation is the only effective intervention to reduce overproduction of protoporphyrin, but is considered only in patients who have developed protoporphyric hepatopathy.",
"   </p>",
"   <p>",
"    The following have been recommended in patients with uncomplicated disease. (See",
"    <a class=\"local\" href=\"#H3912296\">",
"     'Treatment and management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Protection from exposure to sunlight is the mainstay of treatment. This may include clothing that is effective in blocking sunlight and significant adjustments in lifestyle. Vitamin D supplements should be given to all patients with EPP to protect from vitamin D deficiency.",
"     </li>",
"     <li>",
"      We suggest the use of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      (pharmaceutical grade), which may partially increase sunlight tolerance (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Other available treatments include oral cysteine, narrow-wave UVB phototherapy, and an analogue of alpha-melanocyte stimulating hormone currently undergoing clinical trials.",
"     </li>",
"     <li>",
"      Avoidance of excess alcohol, acute viral hepatitis, drug-induced liver injury, or other intercurrent problems that may cause liver damage. Hepatitis A and B vaccination is important.",
"     </li>",
"     <li>",
"      Aggressive management is warranted for protoporphyric hepatopathy. (See",
"      <a class=\"local\" href=\"#H3912324\">",
"       'Treatment of gallstones and protoporphyric hepatopathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest a treatment regimen including intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"       hemin",
"      </a>",
"      , plasmapheresis, ursodeoxycholic acid,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"       cholestyramine",
"      </a>",
"      , and vitamin E (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The aim is to bridge the patient to recovery of liver function or to liver transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with severe liver disease who have not responded to the above treatment regimen, liver transplantation or supportive care are the only available options.",
"   </p>",
"   <p>",
"    Bone marrow transplantation is a treatment option in patients who have recovered sufficiently from a severe episode of protoporphyric hepatopathy, or are experiencing recurrence of liver disease after liver transplantation. (See",
"    <a class=\"local\" href=\"#H3912338\">",
"     'Bone marrow transplantation'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/1\">",
"      MAGNUS IA, JARRETT A, PRANKERD TA, RIMINGTON C. Erythropoietic protoporphyria. A new porphyria syndrome with solar urticaria due to protoporphyrinaemia. Lancet 1961; 2:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/2\">",
"      Goodwin RG, Kell WJ, Laidler P, et al. Photosensitivity and acute liver injury in myeloproliferative disorder secondary to late-onset protoporphyria caused by deletion of a ferrochelatase gene in hematopoietic cells. Blood 2006; 107:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/3\">",
"      Sarkany RP, Ross G, Willis F. Acquired erythropoietic protoporphyria as a result of myelodysplasia causing loss of chromosome 18. Br J Dermatol 2006; 155:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/4\">",
"      DeLeo VA, Poh-Fitzpatrick M, Mathews-Roth M, Harber LC. Erythropoietic protoporphyria. 10 years experience. Am J Med 1976; 60:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/5\">",
"      Poh-Fitzpatrick MB. Erythropoietic porphyrias: current mechanistic, diagnostic, and therapeutic considerations. Semin Hematol 1977; 14:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/6\">",
"      Elder GH, Smith SG, Smyth SJ. Laboratory investigation of the porphyrias. Ann Clin Biochem 1990; 27 ( Pt 5):395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/7\">",
"      Went LN, Klasen EC. Genetic aspects of erythropoietic protoporphyria. Ann Hum Genet 1984; 48:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/8\">",
"      Peterka ES, Fusaro RM, Goltz RW. Erythropoietic protoporphyria. II. Histological and histochemical studies of cutaneous lesions. Arch Dermatol 1965; 92:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/9\">",
"      Baart de la Faille H, Bijlmer-Iest JC, van Hattum J, et al. Erythropoietic protoporphyria: clinical aspects with emphasis on the skin. Curr Probl Dermatol 1991; 20:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/10\">",
"      Schmidt H, Snitker G, Thomsen K, Lintrup J. Erythropoietic protoporphyria. A clinical study based on 29 cases in 14 families. Arch Dermatol 1974; 110:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/11\">",
"      Bopp C, Bakos L, da Gra&ccedil;a Busko M. Erythropoietic protoporphyria. Int J Biochem 1980; 12:909.",
"     </a>",
"    </li>",
"    <li>",
"     Cox TM. Protoporphyria. In: Porphyrin Handbook, Part II, Kadish KM, Smith K, Guilard R (Eds), Academic Press, San Diego 2003. p.121.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/13\">",
"      Gigli I, Schothorst AA, Soter NA, Pathak MA. Erythropoietic protoporphyria. Photoactivation of the complement system. J Clin Invest 1980; 66:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/14\">",
"      Epstein JH, Tuffanelli DL, Epstein WL. Cutaneous changes in the porphyrias. A microscopic study. Arch Dermatol 1973; 107:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/15\">",
"      Ryan EA, Madill GT. Electron microscopy of the skin in erythropoietic protoporphyria. Br J Dermatol 1968; 80:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/16\">",
"      Ryan EA. Histochemistry of the skin in erythropoietic protoporphyria. Br J Dermatol 1966; 78:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/17\">",
"      Sasai Y. Erythropoietic protoporphyria. Histochemical study of hyaline material. Acta Derm Venereol 1973; 53:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/18\">",
"      Lim HW. Pathophysiology of cutaneous lesions in porphyrias. Semin Hematol 1989; 26:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/19\">",
"      Doss MO, Frank M. Hepatobiliary implications and complications in protoporphyria, a 20-year study. Clin Biochem 1989; 22:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/20\">",
"      Cripps DJ, Scheuer PJ. Hepatobiliary changes in erythropoietic protoporphyria. Arch Pathol 1965; 80:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/21\">",
"      Holme SA, Anstey AV, Finlay AY, et al. Erythropoietic protoporphyria in the U.K.: clinical features and effect on quality of life. Br J Dermatol 2006; 155:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/22\">",
"      Avner DL, Lee RG, Berenson MM. Protoporphyrin-induced cholestasis in the isolated in situ perfused rat liver. J Clin Invest 1981; 67:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/23\">",
"      Poh-Fitzpatrick MB, Whitlock RT, Leftkowitch JH. Changes in protoporphyrin distribution dynamics during liver failure and recovery in a patient with protoporphyria and Epstein-Barr viral hepatitis. Am J Med 1986; 80:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/24\">",
"      Bonkovsky HL, Schned AR. Fatal liver failure in protoporphyria. Synergism between ethanol excess and the genetic defect. Gastroenterology 1986; 90:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/25\">",
"      Minder EI, Gouya L, Schneider-Yin X, Deybach JC. A genotype-phenotype correlation between null-allele mutations in the ferrochelatase gene and liver complication in patients with erythropoietic protoporphyria. Cell Mol Biol (Noisy-le-grand) 2002; 48:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/26\">",
"      Bloomer J, Bruzzone C, Zhu L, et al. Molecular defects in ferrochelatase in patients with protoporphyria requiring liver transplantation. J Clin Invest 1998; 102:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/27\">",
"      Lyoumi S, Abitbol M, Rainteau D, et al. Protoporphyrin retention in hepatocytes and Kupffer cells prevents sclerosing cholangitis in erythropoietic protoporphyria mouse model. Gastroenterology 2011; 141:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/28\">",
"      Bloomer JR. The liver in protoporphyria. Hepatology 1988; 8:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/29\">",
"      Key NS, Rank JM, Freese D, et al. Hemolytic anemia in protoporphyria: possible precipitating role of liver failure and photic stress. Am J Hematol 1992; 39:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/30\">",
"      Sarkany RP, Cox TM. Autosomal recessive erythropoietic protoporphyria: a syndrome of severe photosensitivity and liver failure. QJM 1995; 88:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/31\">",
"      Bloomer JR, Phillips MJ, Davidson DL, et al. Hepatic disease in erythropoietic protoporphyria. Am J Med 1975; 58:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/32\">",
"      Bloomer JR, Rank JM, Payne WD, et al. Follow-up after liver transplantation for protoporphyric liver disease. Liver Transpl Surg 1996; 2:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/33\">",
"      MacDonald DM, Germain D, Perrot H. The histopathology and ultrastructure of liver disease in erythropoietic protoporphyria. Br J Dermatol 1981; 104:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/34\">",
"      Klatskin G, Bloomer JR. Birefringence of hepatic pigment deposits in erythropoietic protoporphyria. Specificity of polarization microscopy in the identification of hepatic protoporphyrin deposits. Gastroenterology 1974; 67:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/35\">",
"      Matilla A, Molland EA. A light and electron microscopic study of the liver in case of erythrohepatic protoporphyria and in griseofulvin-induced porphyria in mice. J Clin Pathol 1974; 27:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/36\">",
"      Bloomer JR, Enriquez R. Evidence that hepatic crystalline deposits in a patient with protoporphyria are composed of protoporphyrin. Gastroenterology 1982; 82:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/37\">",
"      Barnes HD, Hurworth E, Millar JH. Erythropoietic porphyrin hepatitis. J Clin Pathol 1968; 21:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/38\">",
"      Cripps DJ, Scheuer PJ. Hepatobiliary changes in erythropoietic protoporphyria. Arch Pathol 1965; 80:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/39\">",
"      Rademakers LH, Cleton MI, Kooijman C, et al. Ultrastructural aspects of the liver in erythrohepatic protoporphyria. Curr Probl Dermatol 1991; 20:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/40\">",
"      Herbert A, Corbin D, Williams A, et al. Erythropoietic protoporphyria: unusual skin and neurological problems after liver transplantation. Gastroenterology 1991; 100:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/41\">",
"      Rank JM, Carithers R, Bloomer J. Evidence for neurological dysfunction in end-stage protoporphyric liver disease. Hepatology 1993; 18:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/42\">",
"      Hengstman GJ, de Laat KF, Jacobs B, van Engelen BG. Sensorimotor axonal polyneuropathy without hepatic failure in erythropoietic protoporphyria. J Clin Neuromuscul Dis 2009; 11:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/43\">",
"      Wahlin S, Floderus Y, St&aring;l P, Harper P. Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics. J Intern Med 2011; 269:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/44\">",
"      Holme SA, Worwood M, Anstey AV, et al. Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria. Blood 2007; 110:4108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/45\">",
"      Lyoumi S, Abitbol M, Andrieu V, et al. Increased plasma transferrin, altered body iron distribution, and microcytic hypochromic anemia in ferrochelatase-deficient mice. Blood 2007; 109:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/46\">",
"      Delaby C, Lyoumi S, Ducamp S, et al. Excessive erythrocyte PPIX influences the hematologic status and iron metabolism in patients with dominant erythropoietic protoporphyria. Cell Mol Biol (Noisy-le-grand) 2009; 55:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/47\">",
"      Gouya L, Deybach JC, Lamoril J, et al. Modulation of the phenotype in dominant erythropoietic protoporphyria by a low expression of the normal ferrochelatase allele. Am J Hum Genet 1996; 58:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/48\">",
"      Gouya L, Puy H, Lamoril J, et al. Inheritance in erythropoietic protoporphyria: a common wild-type ferrochelatase allelic variant with low expression accounts for clinical manifestation. Blood 1999; 93:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/49\">",
"      Jong CT, Finlay AY, Pearse AD, et al. The quality of life of 790 patients with photodermatoses. Br J Dermatol 2008; 159:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/50\">",
"      Madu AE, Whittaker SJ. Erythropoietic protoporphyria in pregnancy. J Obstet Gynaecol 2006; 26:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/51\">",
"      Poh-Fitzpatrick MB. Human protoporphyria: reduced cutaneous photosensitivity and lower erythrocyte porphyrin levels during pregnancy. J Am Acad Dermatol 1997; 36:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/52\">",
"      Bottomley SS, Tanaka M, Everett MA. Diminished erythroid ferrochelatase activity in protoporphyria. J Lab Clin Med 1975; 86:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/53\">",
"      Bonkowsky HL, Bloomer JR, Ebert PS, Mahoney MJ. Heme synthetase deficiency in human protoporphyria. Demonstration of the defect in liver and cultured skin fibroblasts. J Clin Invest 1975; 56:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/54\">",
"      Gouya L, Puy H, Robreau AM, et al. The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nat Genet 2002; 30:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/55\">",
"      Gouya L, Martin-Schmitt C, Robreau AM, et al. Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria. Am J Hum Genet 2006; 78:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/56\">",
"      Nakahashi Y, Taketani S, Okuda M, et al. Molecular cloning and sequence analysis of cDNA encoding human ferrochelatase. Biochem Biophys Res Commun 1990; 173:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/57\">",
"      Whitcombe DM, Carter NP, Albertson DG, et al. Assignment of the human ferrochelatase gene (FECH) and a locus for protoporphyria to chromosome 18q22. Genomics 1991; 11:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/58\">",
"      Taketani S, Inazawa J, Nakahashi Y, et al. Structure of the human ferrochelatase gene. Exon/intron gene organization and location of the gene to chromosome 18. Eur J Biochem 1992; 205:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/59\">",
"      Risheg H, Chen FP, Bloomer JR. Genotypic determinants of phenotype in North American patients with erythropoietic protoporphyria. Mol Genet Metab 2003; 80:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/60\">",
"      Wiman A, Floderus Y, Harper P. Novel mutations and phenotypic effect of the splice site modulator IVS3-48C in nine Swedish families with erythropoietic protoporphyria. J Hum Genet 2003; 48:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/61\">",
"      Parker M, Corrigall AV, Hift RJ, Meissner PN. Molecular characterization of erythropoietic protoporphyria in South Africa. Br J Dermatol 2008; 159:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/62\">",
"      Schneider-Yin X, Mamet R, Minder EI, Schoenfeld N. Biochemical and molecular diagnosis of erythropoietic protoporphyria in an Ashkenazi Jewish family. J Inherit Metab Dis 2008; 31 Suppl 2:S363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/63\">",
"      Whatley SD, Ducamp S, Gouya L, et al. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet 2008; 83:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/64\">",
"      Wang Y, Langer NB, Shaw GC, et al. Abnormal mitoferrin-1 expression in patients with erythropoietic protoporphyria. Exp Hematol 2011; 39:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/65\">",
"      Scholnick P, Marver HS, Schmid R. Erythropoietic protoporphyria: evidence for multiple sites of excess protoporphyrin formation. J Clin Invest 1971; 50:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/66\">",
"      Sandberg S, Talstad I, H&oslash;vding G, Bjelland N. Light-induced release of protoporphyrin, but not of zinc protoporphyrin, from erythrocytes in a patient with greatly elevated erythrocyte protoporphyrin. Blood 1983; 62:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/67\">",
"      Piomelli S, Lamola AA, Poh-Fitzpatrick MF, et al. Erythropoietic protoporphyria and lead intoxication: the molecular basis for difference in cutaneous photosensitivity. I. Different rates of disappearance of protoporphyrin from the erythrocytes, both in vivo and in vitro. J Clin Invest 1975; 56:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/68\">",
"      Sassaroli M, da Costa R, V&auml;&auml;n&auml;nen H, et al. Distribution of erythrocyte free porphyrin content in erythropoietic protoporphyria. J Lab Clin Med 1992; 120:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/69\">",
"      Clark KG, Nicholson DC. Erythrocyte protoporphyrin and iron uptake in erythropoietic protoporphyria. Clin Sci 1971; 41:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/70\">",
"      Sandberg S, Brun A. Light-induced protoporphyrin release from erythrocytes in erythropoietic protoporphyria. J Clin Invest 1982; 70:693.",
"     </a>",
"    </li>",
"    <li>",
"     Kochevar IE. Primary processes in photobiology and photosensitization. In: Photoimmunology: An Update, Krutman J, Elmats C (Eds), Blackwell, New York 1995. p.19.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/72\">",
"      Sandberg S, Romslo I. Porphyrin-induced photodamage at the cellular and the subcellular level as related to the solubility of the porphyrin. Clin Chim Acta 1981; 109:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/73\">",
"      Goldstein BD, Harber LC. Erythropoietic protoporphyria: lipid peroxidation and red cell membrane damage associated with photohemolysis. J Clin Invest 1972; 51:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/74\">",
"      De Goeij AF, Van Steveninck J. Photodynamic effects of protoporphyrin on cholesterol and unsaturated fatty acids in erythrocyte membranes in protoporphyria and in normal red blood cells. Clin Chim Acta 1976; 68:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/75\">",
"      Poh-Fitzpatrick MB. Molecular and cellular mechanisms of porphyrin photosensitization. Photodermatol 1986; 3:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/76\">",
"      Lim HW, Gigli I. Role of complement in porphyrin-induced photosensitivity. J Invest Dermatol 1981; 76:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/77\">",
"      Lim HW, Poh-Fitzpatrick MB, Gigli I. Activation of the complement system in patients with porphyrias after irradiation in vivo. J Clin Invest 1984; 74:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/78\">",
"      Hastka J, Lasserre JJ, Schwarzbeck A, et al. Zinc protoporphyrin in anemia of chronic disorders. Blood 1993; 81:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/79\">",
"      Anderson KE, Sassa S, Peterson CM, Kappas A. Increased erythrocyte uroporphyrinogen-l-synthetase, delta-aminolevulinic acid dehydratase and protoporphyrin in hemolytic anemias. Am J Med 1977; 63:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/80\">",
"      Mathews-Roth MM, Pathak MA, Fitzpatrick TB, et al. Beta-carotene as a photoprotective agent in erythropoietic protoporphyria. N Engl J Med 1970; 282:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/81\">",
"      Lewis MB. The effect of -carotene on serum vitamin A levels in erythropoietic protoporphyria. Australas J Dermatol 1972; 13:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/82\">",
"      Baart de la Faille H, Suurmond D, Went LN, et al. -Carotene as a treatment for photohypersensitivity due to erythropoietic protoporphyria. Dermatologica 1972; 145:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/83\">",
"      Mathews-Roth MM, Pathak UA, Fitzpatrick TB, et al. Beta-carotene as an oral photoprotective agent in erythropoietic protoporphyria. JAMA 1974; 228:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/84\">",
"      Krook G, Haeger-Aronsen B. Erythrohepatic protoporphyria and its treatment with beta-carotene. Acta Derm Venereol 1974; 54:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/85\">",
"      Beckert E, Metz J. [Erythropoietic protoporthyria. Clinical aspects and therapy]. Fortschr Med 1976; 94:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/86\">",
"      Goerz G, Ippen H. [Treatment of photodermatoses with carotinoids (author's transl)]. Dtsch Med Wochenschr 1977; 102:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/87\">",
"      Zaynoun ST, Hunter JA, Darby FJ, et al. The treatment of erythropoietic protoporphyria. Experience with beta-carotene. Br J Dermatol 1977; 97:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/88\">",
"      Corbett MF, Herxheimer A, Magnus IA, et al. The long term treatment with beta-carotene in erythropoietic protoporphyria: a controlled trial. Br J Dermatol 1977; 97:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/89\">",
"      Mathews-Roth MM, Pathak MA, Fitzpatrick TB, et al. Beta carotene therapy for erythropoietic protoporphyria and other photosensitivity diseases. Arch Dermatol 1977; 113:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/90\">",
"      Niebauer G, Mischer P, Formanek I. Light-sensitive dermatoses in children. Mod Probl Paediatr 1976; 20:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/91\">",
"      Thomsen K, Schmidt H, Fischer A. Beta-carotene in erythropoietic protoporphyria: 5 years' experience. Dermatologica 1979; 159:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/92\">",
"      Barth J, Fickweiler E, Harnack K, et al. [Beta-carotene treatment of protoporphyrias and polymorphic light dermatoses]. Dermatol Monatsschr 1984; 170:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/93\">",
"      Wennersten G. Carotenoid treatment for light sensitivity: a reappraisal and six years' experience. Acta Derm Venereol 1980; 60:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/94\">",
"      de S&eacute;lys R, Decroix J, Frankart M, et al. [Erythropoietic protoporphyria]. Ann Dermatol Venereol 1988; 115:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/95\">",
"      Lehmann P, Scharffetter K, Kind P, Goerz G. [Erythropoietic protoporphyria: synopsis of 20 patients]. Hautarzt 1991; 42:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/96\">",
"      von Laar J, Stahl W, Bolsen K, et al. Beta-carotene serum levels in patients with erythropoietic protoporphyria on treatment with the synthetic all-trans isomer or a natural isomeric mixture of beta-carotene. J Photochem Photobiol B 1996; 33:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/97\">",
"      Minder EI, Schneider-Yin X, Steurer J, Bachmann LM. A systematic review of treatment options for dermal photosensitivity in erythropoietic protoporphyria. Cell Mol Biol (Noisy-le-grand) 2009; 55:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/98\">",
"      Boffa MJ, Ead RD, Reed P, Weinkove C. A double-blind, placebo-controlled, crossover trial of oral vitamin C in erythropoietic protoporphyria. Photodermatol Photoimmunol Photomed 1996; 12:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/99\">",
"      Mathews-Roth MM, Rosner B, Benfell K, Roberts JE. A double-blind study of cysteine photoprotection in erythropoietic protoporphyria. Photodermatol Photoimmunol Photomed 1994; 10:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/100\">",
"      Mathews-Roth MM, Rosner B. Long-term treatment of erythropoietic protoporphyria with cysteine. Photodermatol Photoimmunol Photomed 2002; 18:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/101\">",
"      Bijlmer-Iest JC, Baart de la Faille H, van Asbeck BS, et al. Protoporphyrin photosensitivity cannot be attenuated by oral N-acetylcysteine. Photodermatol Photoimmunol Photomed 1992; 9:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/102\">",
"      Norris PG, Baker CS, Roberts JE, Hawk JL. Treatment of erythropoietic protoporphyria with N-acetylcysteine. Arch Dermatol 1995; 131:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/103\">",
"      Fusaro RM, Johnson JA. Protection against long ultraviolet and/or visible light with topical dihydroxyacetone. Implications for the mechanism of action of the sunscreen combination, dihydroxyacetone/naphthoquinone. Dermatologica 1975; 150:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/104\">",
"      Fusaro RM, Rice EG. The maillard reaction for sunlight protection. Ann N Y Acad Sci 2005; 1043:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/105\">",
"      Rice EG. Dihydroxyacetone naphthoquinone protection against photosensitivity. Dermatologica 1976; 153:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/106\">",
"      Collins P, Ferguson J. Narrow-band UVB (TL-01) phototherapy: an effective preventative treatment for the photodermatoses. Br J Dermatol 1995; 132:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/107\">",
"      Harms JH, Lautenschlager S, Minder CE, Minder EI. Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone. Photochem Photobiol 2009; 85:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/108\">",
"      Gordeuk VR, Brittenham GM, Hawkins CW, et al. Iron therapy for hepatic dysfunction in erythropoietic protoporphyria. Ann Intern Med 1986; 105:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/109\">",
"      Holme SA, Thomas CL, Whatley SD, et al. Symptomatic response of erythropoietic protoporphyria to iron supplementation. J Am Acad Dermatol 2007; 56:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/110\">",
"      Milligan A, Graham-Brown RA, Sarkany I, Baker H. Erythropoietic protoporphyria exacerbated by oral iron therapy. Br J Dermatol 1988; 119:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/111\">",
"      McClements BM, Bingham A, Callender ME, Trimble ER. Erythropoietic protoporphyria and iron therapy. Br J Dermatol 1990; 122:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/112\">",
"      Wahlin S, Aschan J, Bj&ouml;rnstedt M, et al. Curative bone marrow transplantation in erythropoietic protoporphyria after reversal of severe cholestasis. J Hepatol 2007; 46:174.",
"     </a>",
"    </li>",
"    <li>",
"     Sood G, Anderson K. Porphyrias. In: Evidence-Based Hematology, Crowther M, Ginsberg J, Schunemann H, et al. (Eds), Wiley, Hoboken 2008. p.229.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/114\">",
"      Dowman JK, Gunson BK, Mirza DF, et al. UK experience of liver transplantation for erythropoietic protoporphyria. J Inherit Metab Dis 2011; 34:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/115\">",
"      Bloomer JR, Pierach CA. Effect of hematin administration to patients with protoporphyria and liver disease. Hepatology 1982; 2:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/116\">",
"      Lamon JM, Poh-Fitzpatrick MB, Lamola AA. Hepatic protoporphyrin production in human protoporphyria. Effects of intravenous hematin and analysis of erythrocyte protoporphyrin distribution. Gastroenterology 1980; 79:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/117\">",
"      Reichheld JH, Katz E, Banner BF, et al. The value of intravenous heme-albumin and plasmapheresis in reducing postoperative complications of orthotopic liver transplantation for erythropoietic protoporphyria. Transplantation 1999; 67:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/118\">",
"      Wahlin S, Harper P. Pretransplant albumin dialysis in erythropoietic protoporphyria: a costly detour. Liver Transpl 2007; 13:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/119\">",
"      Krishnamurthy P, Xie T, Schuetz JD. The role of transporters in cellular heme and porphyrin homeostasis. Pharmacol Ther 2007; 114:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/120\">",
"      Eichbaum QG, Dzik WH, Chung RT, Szczepiorkowski ZM. Red blood cell exchange transfusion in two patients with advanced erythropoietic protoporphyria. Transfusion 2005; 45:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/121\">",
"      van Wijk HJ, van Hattum J, Baart de la Faille H, et al. Blood exchange and transfusion therapy for acute cholestasis in protoporphyria. Dig Dis Sci 1988; 33:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/122\">",
"      Gross U, Frank M, Doss MO. Hepatic complications of erythropoietic protoporphyria. Photodermatol Photoimmunol Photomed 1998; 14:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/123\">",
"      Rademakers LH, Cleton MI, Kooijman C, et al. Early involvement of hepatic parenchymal cells in erythrohepatic protoporphyria? An ultrastructural study of patients with and without overt liver disease and the effect of chenodeoxycholic acid treatment. Hepatology 1990; 11:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/124\">",
"      Ishibashi A, Ogata R, Sakisaka S, et al. Erythropoietic protoporphyria with fatal liver failure. J Gastroenterol 1999; 34:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/125\">",
"      Stathers GM. Porphyrin-binding effect of cholestyramine. Results of in-vitro and in-vivo studies. Lancet 1966; 2:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/126\">",
"      Komatsu H, Ishii K, Imamura K, et al. A case of erythropoietic protoporphyria with liver cirrhosis suggesting a therapeutic value of supplementation with alpha-tocopherol. Hepatol Res 2000; 18:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/127\">",
"      Wells MM, Golitz LE, Bender BJ. Erythropoietic protoporphyria with hepatic cirrhosis. Arch Dermatol 1980; 116:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/128\">",
"      Anstey AV, Hift RJ. Liver disease in erythropoietic protoporphyria: insights and implications for management. Gut 2007; 56:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/129\">",
"      Wahlin S, Stal P, Adam R, et al. Liver transplantation for erythropoietic protoporphyria in Europe. Liver Transpl 2011; 17:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/130\">",
"      McGuire BM, Bonkovsky HL, Carithers RL Jr, et al. Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl 2005; 11:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/131\">",
"      Wahlin S, Srikanthan N, Hamre B, et al. Protection from phototoxic injury during surgery and endoscopy in erythropoietic protoporphyria. Liver Transpl 2008; 14:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/132\">",
"      Do KD, Banner BF, Katz E, et al. Benefits of chronic plasmapheresis and intravenous heme-albumin in erythropoietic protoporphyria after orthotopic liver transplantation. Transplantation 2002; 73:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/133\">",
"      Rand EB, Bunin N, Cochran W, et al. Sequential liver and bone marrow transplantation for treatment of erythropoietic protoporphyria. Pediatrics 2006; 118:e1896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/134\">",
"      Pawliuk R, Bachelot T, Wise RJ, et al. Long-term cure of the photosensitivity of murine erythropoietic protoporphyria by preselective gene therapy. Nat Med 1999; 5:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/135\">",
"      Fontanellas A, Mazurier F, Landry M, et al. Reversion of hepatobiliary alterations By bone marrow transplantation in a murine model of erythropoietic protoporphyria. Hepatology 2000; 32:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/136\">",
"      Poh-Fitzpatrick MB, Wang X, Anderson KE, et al. Erythropoietic protoporphyria: altered phenotype after bone marrow transplantation for myelogenous leukemia in a patient heteroallelic for ferrochelatase gene mutations. J Am Acad Dermatol 2002; 46:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/137\">",
"      Wahlin S, Harper P. The role for BMT in erythropoietic protoporphyria. Bone Marrow Transplant 2010; 45:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/29/15834/abstract/138\">",
"      Anstey AV, Hift RJ. Liver disease in erythropoietic protoporphyria: insights and implications for management. Postgrad Med J 2007; 83:739.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7125 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-BE0BA8F269-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_29_15834=[""].join("\n");
var outline_f15_29_15834=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3912345\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3912139\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3912146\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7689197\">",
"      Adult onset EPP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3912153\">",
"      PREVALENCE AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3912160\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3912167\">",
"      Skin findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3912195\">",
"      Hepatobiliary manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7689019\">",
"      - Gallstones",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7689026\">",
"      - Liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7689041\">",
"      Associated peripheral neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7688953\">",
"      Hematologic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7689066\">",
"      Quality of life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7688960\">",
"      Long term course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3912202\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3912210\">",
"      Molecular pathology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3912217\">",
"      - EPP due to FECH deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3912224\">",
"      - X-linked protoporphyria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3912238\">",
"      - Other molecular defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3912245\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3912289\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8738170\">",
"      Erythrocyte protoporphyrin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8738177\">",
"      Plasma porphyrins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8738184\">",
"      DNA studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3912296\">",
"      TREATMENT AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3912303\">",
"      Beta-carotene for photoprotection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3912310\">",
"      Other methods of photoprotection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3912317\">",
"      Additional management considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3912324\">",
"      Treatment of gallstones and protoporphyric hepatopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21714462\">",
"      - Gallstones",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8738288\">",
"      - Management of hepatopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3912331\">",
"      Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3912338\">",
"      Bone marrow transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21714418\">",
"      EVALUATION AND MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3912345\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12440608\">",
"      Disease overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3912352\">",
"      Suspecting and confirming the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3912359\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7125\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7125|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/31/25077\" title=\"figure 1\">",
"      Heme synthesis and porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7125|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/1/15390\" title=\"table 1\">",
"      Photosensitive disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/55/30588\" title=\"table 2\">",
"      Heme intermediates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/23/4477\" title=\"table 3\">",
"      Excretion patterns",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10374?source=related_link\">",
"      Approach to the patient with incidental gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36441?source=related_link\">",
"      Causes of congenital and acquired sideroblastic anemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=related_link\">",
"      Clinical manifestations and diagnosis of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3398?source=related_link\">",
"      Management of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=related_link\">",
"      Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=related_link\">",
"      Porphyrias: An overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_29_15835="IDUS accuracy versus ERCP";
var content_f15_29_15835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intraductal ultrasound (IDUS) versus endoscopic retrograde cholangiopancreatography (ERCP) for evaluation of bile duct strictures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        ERCP (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        IDUS (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        p value",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Sensitivity",
"        </strong>",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        0.10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Specificity",
"        </strong>",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        0.76",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Accuracy",
"        </strong>",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        0.13",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Vazquez-Sequeiros E, Baron TH, Clain JE, et al. Evaluation of indeterminate bile duct strictures by intraductal US. Gastrointest Endosc 2002; 56:372.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_29_15835=[""].join("\n");
var outline_f15_29_15835=null;
var title_f15_29_15836="Frisen scale";
var content_f15_29_15836=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F73887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F73887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modified Fris&eacute;n Scale for grading papilledema",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Stage 0: Normal optic disc or not a disc but no edema/swelling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. Prominence of the retinal nerve fiber layer at the nasal, superior and inferior poles in inverse proportion to disc diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. Radial nerve fiber layer striations, without tortuosity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Stage I: Minimal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. C-shaped halo that is subtle and grayish with a temporal gap; obscures underlying retinal details",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. Disruption of normal radial NFL arrangement striations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C. Temporal disc margin normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Stage II: Low degree",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. Circumferential halo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. Elevation - nasal border",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C. No major vessel obscuration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Stage III: Moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. Obscuration of one or more segments of major blood vessels leaving disc",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. Circumferential halo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C. Elevation - all borders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D. Halo - irregular outer fringe with finger-like extensions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Stage IV: Marked",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. Total obscuration on the disc of a segment of a major blood vessel on the disc",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. Elevation - whole nerve head, including the cup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C. Border obscuration - complete",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D. Halo - complete",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Stage V: Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. Partial obscuration of all vessels on disc and total obscuration of at least one vessel on disc",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Fris&eacute;n, L. Swelling of the optic nerve head: a staging scheme. J Neurol Neurosurg Psychiatry 1982; 45:13.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_29_15836=[""].join("\n");
var outline_f15_29_15836=null;
var title_f15_29_15837="Adenocarcinoma histologic molecular radiologic subtypes";
var content_f15_29_15837=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F74551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F74551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Adenocarcinoma histologic molecular radiologic subtypes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Histological subtype predominant",
"       </td>",
"       <td class=\"subtitle1\">",
"        Molecular features",
"       </td>",
"       <td class=\"subtitle1\">",
"        CT scan appearance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Nonmucinous adenocarcinoma in situ and minimally invasive adenocarcinoma",
"       </td>",
"       <td>",
"        TTF-1 + (100 percent)",
"       </td>",
"       <td rowspan=\"3\">",
"        GGN, part-solid nodule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EGFR mutation never smokers: 10-30 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        KRAS mutation smokers: 10-30 percent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Lepidic (nonmucinous)",
"       </td>",
"       <td>",
"        TTF-1 + (100 percent)",
"       </td>",
"       <td>",
"        Part solid nodule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EGFR mutation never smokers: 10-30 percent",
"       </td>",
"       <td rowspan=\"4\">",
"        GGN or solid nodule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EGFR amplification: 20-50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        KRAS mutation smokers: 10 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BRAF mutations: 5 percent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"7\">",
"        Papillary",
"       </td>",
"       <td>",
"        TTF-1 + (90-100 percent)",
"       </td>",
"       <td rowspan=\"7\">",
"        Solid nodule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EGFR mutation: 10-30 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EGFR amplification: 20-50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        KRAS mutation 3 percent (lack of KRAS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ERBB2 mutations: 3 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        p53 mutations: 30 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BRAF mutations: 5 percent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        Acinar",
"       </td>",
"       <td>",
"        TTF-1 + or -",
"       </td>",
"       <td rowspan=\"6\">",
"        Solid nodule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        KRAS mutation in smokers (20 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EGFR mutations &lt;10 percent nonsmokers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EGFR amplification: 10 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EML4/ALK translocation: &gt;5 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        P53 mutations: 40 percent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Micropapillary",
"       </td>",
"       <td>",
"        KRAS mutations (33 percent)",
"       </td>",
"       <td rowspan=\"3\">",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EGFR mutations (20 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BRAF mutations (20 percent)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"9\">",
"        Solid",
"       </td>",
"       <td>",
"        TTF-1 (70 percent)",
"       </td>",
"       <td rowspan=\"9\">",
"        Solid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MUC1 positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        KRAS mutation smokers: 10-30 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EGFR mutation never smokers: 10-30 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EGFR amplification: 20-50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EML4/ALK translocation &gt;5 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        p53 mutation: 50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LRP1B mutations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        INHBA mutations",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Invasive mucinous adenocarcinoma",
"       </td>",
"       <td>",
"        TTF-1 (0-33 percent positive)",
"       </td>",
"       <td rowspan=\"4\">",
"        Consolidation, air bronchograms; less often GGO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        KRAS mutation: 80-100 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No EGFR mutation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MUC5+ MUC6+ MUC2+",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EGFR: epidermal growth factor receptor; GGN: ground-glass nodule; GGO: ground-glass opacity; TTF: thyroid transcription factor.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011; 6:244. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_29_15837=[""].join("\n");
var outline_f15_29_15837=null;
var title_f15_29_15838="Contents: Pediatric ophthalmology";
var content_f15_29_15838=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric ophthalmology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric ophthalmology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Conjunctiva; episclera and sclera",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/17/20760\">",
"           Conjunctivitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/23/5496\">",
"           Approach to the child with leukocoria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/59/24505\">",
"           Visual development and vision assessment in infants and children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Eye trauma and ocular emergencies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/34/7718\">",
"           Child abuse: Anatomy and pathogenesis of retinal hemorrhages after abusive head trauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/7/20602\">",
"           Child abuse: Eye findings in children with abusive head trauma (AHT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/50/34600\">",
"           Corneal abrasions and corneal foreign bodies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Eyelids",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/38/19048\">",
"           Blepharitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Glaucoma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/31/41463\">",
"           Overview of glaucoma in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/57/5016\">",
"           Primary infantile glaucoma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lacrimal system",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/58/7079\">",
"           Approach to the child with persistent tearing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/42/29350\">",
"           Nasolacrimal duct obstruction (dacryostenosis) in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lens",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/14/22761\">",
"           Cataract in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/37/41557\">",
"           Ectopia lentis (dislocated lens) in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neuro-ophthalmology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/47/6906\">",
"           Congenital anomalies and acquired abnormalities of the optic nerve",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/44/12999\">",
"           Fourth cranial nerve (trochlear nerve) palsy in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/32/32262\">",
"           Horner's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/15/20726\">",
"           Myopathies affecting the extraocular muscles in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/15/9464\">",
"           Optic neuritis: Pathophysiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/15/29944\">",
"           Optic neuritis: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/0/1034\">",
"           Pendular nystagmus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/2/43046\">",
"           Sixth cranial nerve (abducens nerve) palsy in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/8/28806\">",
"           Supranuclear disorders of gaze in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/34/40487\">",
"           Third cranial nerve (oculomotor nerve) palsy in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Premature infant",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/32/10762\">",
"           Retinopathy of prematurity",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Strabismus and amblyopia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/52/41800\">",
"           Causes of horizontal strabismus in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/10/26790\">",
"           Causes of vertical strabismus in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/8/34951\">",
"           Evaluation and management of strabismus in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/61/8153\">",
"           Overview of amblyopia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/61/28628\">",
"           Refractive errors in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/24/27018\">",
"           Overview of retinoblastoma",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-801C55F7FB-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f15_29_15838=[""].join("\n");
var outline_f15_29_15838=null;
var title_f15_29_15839="Storz pediatric video laryngoscope";
var content_f15_29_15839=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Storz pediatric video laryngoscope",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 294px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; 2011. Photo courtesy of KARL STORZ Endoscopy-America, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_29_15839=[""].join("\n");
var outline_f15_29_15839=null;
